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ABSTRACT OF THE DISSERTATION 
Kinetic Analysis and Inhibition Studies of Iron-Dependent Histone Demethylases  
by 
Barbara Gordon Cascella 
Doctor of Philosophy in Chemistry 
Washington University in St. Louis, 2014 
Professor Liviu Mirica, Chair 
 
The research presented herein focuses on the kinetics and inhibition of the KDM4 subfamily of 
Jumonji C (JmjC) domain-containing histone demethylases (HDMs). Belonging to the larger class of 
α-ketoglutarate (αKG)-dependent, non-heme iron monooxygenases, the JmjC-HDMs remove 
methyl groups from mono-, di-, and tri-methylated histone lysine residues through an Fe(IV)-oxo-
catalyzed hydroxylation reaction. JmjC-HDMs have been found to play integral roles in the 
maintenance of genomic integrity as well as in the regulation of transcription. Three KDM4 
members were studied: the mixed H3K9/H3K36 demethylases KDM4A and KDM4C, and the pure 
H3K9 demethylase KDM4E. KDM4C is a hypoxia-inducible factor 1 (HIF-1) target gene and a 
putative oncogene, while KDM4A is found to be overexpressed at the protein level in multiple 
cancers. KDM4E is closely related to KDM4D, which has been found to regulate the tumor 
suppressor p53.  
Three in vitro enzyme activity assays, including a novel continuous O2 consumption assay, were 
employed to determine the kinetics of  the three HDMs. The kinetic parameters of  the three 
substrates, with an H3K9me3 peptide in place of  the full histone substrate, were determined. All 
three HDMs were found to have low apparent affinities for O2, suggesting that these enzymes may 
act as O2 sensors in vivo. αKG was found to inhibit KDM4C competitively with respect to O2, with 
KDM4C displaying optimal activity in vitro at αKG concentrations similar to those found in cancer 
cells. Additionally, a 2.1 Å structure of  KDM4A in complex with Ni(II) and αKG was solved. 
xv 
 
Various avenues were explored in the study of  JmjC-HDM inhibition. First, a small library of  simple 
primary- and secondary- substrate analogs was synthesized and screened against KDM4E. From this 
screen, two small molecules were identified as promising candidates for modification in future 
KDM4 inhibitor design studies. The analogs contained carbon-carbon triple bonds or 1,2,3-triazole 
groups. We find the triazole-containing compounds to be stronger inhibitors of  KDM4E. Several of  
the alkyne-containing compounds were tested in KDM4-templated Huisgen 1,3-dipolar 
cycloaddition studies, with no evidence of  enzyme-driven triazole formation. 
Using a peptidomimetic approach, two novel, modified histone H3(7-11) peptides were synthesized 
and tested for inhibition against KDM4A and KDM4C. Lys residues were modified to incorporate 
two propargyl groups on the terminal nitrogen, with one of the peptides having an additional methyl 
group on the terminal nitrogen to make it quaternary. We find enhanced inhibition of KDM4A and 
KDM4C using the positively charged peptide vs. the neutral peptide. KDM4 members show no 
hydroxylase or demethylase activity toward the methylated peptide, suggesting that modification of 
this peptide could lead to enhanced specific inhibition of JmjC-HDMs. No evidence of HDM-
driven triazole formation was found for either peptide in studies with KDM4A- and KDM4C- azide 
adducts.  
The inhibition of KDM4A with respect to O2 for the pan-selective JmjC-HDM inhibitor JIB-04 was 
explored. KDM4A inhibition by JIB-04 increases with decreasing O2 concentration, suggesting that 
JIB-04 may inhibit KDM4A in part by disrupting the binding of O2. JIB-04 isomers were modeled 
into the KDM4A active site, revealing the predicted basis for JIB-04 isomer-specific inhibition of 
JmjC-HDMs. Finally, a 3.1 Å structure of KDM4A in complex with JIB-04 was solved, revealing 
only a fragment of the inhibitor in the enzyme active site. 
1 
 
   
Chapter 1: Introduction 
1.1 Covalent Modification of  Chromatin 
A nucleosome is an assembly of deoxyribonucleic acid (DNA) wound around an octamer 
protein core composed of four types of histones: H2A, H2B, H3, and H4 (Figure 1.1). Nucleosomes 
string together via linker histones, H1, to form chromatin. Though DNA is packaged into 
chromatin, it is necessary that the genetic information be accessible to cellular machinery for 
replication and transcription. The interplay between the condensed heterochromatin form and the 
transcriptionally active euchromatin form is facilitated through epigenetic events such as DNA 
methylation and covalent histone modification. DNA can be modified through methylation of 
cytosine residues, while histone protein tails, rich in basic residues and protruding from the 
nucleosome core, are subjected to various forms of chemical modification. Aside from the most 
common modifications of methylation and acetylation, basic histone residues can also be 
phosphorylated and ubiquitylated. The histone tail most subjected to modification is the N-terminus 
of histone H3, which is boxed in Figure 1.1.1 
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Figure 1.1. The nucleosome, with the four core histones in different colors (PDB 1AOI).2 
 
There exists a vast network of  proteins in the regulation of  transcription that serve as 
“writers”, “readers”, and “erasers” of  nucleosome modification. Writers are those enzymes that add 
a chemical group to a histone residue or cytosine. Writers include enzymes such as histone 
methyltransfereases (HMTs), histone acetyltransferases (HATs), and DNA methyltransferases 
(DNMTs). Reader proteins function as the interpreters of  the network. Methylated lysine residues 
are often recognized by proteins with chromodomains (e.g. heterochromatin protein 1 (HP1), which 
binds H3K9me2/3)
3 or plant homeodomains (PHDs, e.g. the tumor suppressor ING2). Such protein 
domains contain aromatic cages to stabilize binding to methyllysine, through cation-π interactions, as 
illustrated in Figure 1.2.4-8  
3 
 
 
Figure 1.2. HP1’s interaction with H3K9me3 via cation-π interactions.
9  
Eraser proteins can be recruited to sites of  nucleosome modification to remove the 
modification. Erasers include enzymes such as histone demethylases (HDMs), which are the focus 
of  this dissertation work, and histone deacetylases (HDACs). A recent report illustrates a portion of  
the complex regulatory system of  writers, readers, and erasers in C. elegans that serves to maintain 
proper heterochromatin and euchromatin boundaries.10 Working in concert in the euchromatin 
region are an H3K4me2/1 demethylase and two H3K4 methyltransferases, while in the 
heterochromatin region, the epigenetic memory antagonism protein 1 (EAP-1) reads and binds 
trimethylated H3K9, and subsequently moderates the activities of  H3K9me3 HDMs and HMTs.  
Modification of  histone termini contributes to the regulation of  transcription by affecting 
accessibility of  DNA sequences to transcription machinery (Figure 1.3).11 Chromatin modification 
can disrupt the interaction between the negatively charged DNA and positively charged histone 
protein N-termini.  
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Figure 1.3. Epigenetic events and their effects on chromatin condensation. Adapted from a 
Bio-Rad Laboratories image.   
Acetylation of  lysine residues (Figure 1.4) generally leads to relaxation of  chromatin and 
activation of  transcription, as the modification neutralizes lysine and therefore reduces the overall 
charge of  the histone. The reduction of  positive charge is thought to lessen the affinity between the 
histone and surrounding DNA.12, 13 
Lys
NH2
H
S
O
Glu
-O
O CoA
Lys
NH
O
4 4
+ HS-CoA
 
Figure 1.4. Acetylation of lysine residues leads to neutralization of charge. 
Methylation of lysine histone residues is predominantly accomplished via methyl transfer by 
S-adenosylmethionine (SAM)- dependent histone lysine methyltransferases (KMTs).14 Following 
binding of SAM and deprotonation of the lysine substrate by a KMT, there is a proposed SN2 attack 
of the lysine’s ε nitrogen on the activated SAM cofactor (Figure 1.5).15  Addition of methyl groups to 
5 
 
lysine and arginine residues increases the hydrophobicity of the residue, thus enhancing the residue’s 
interaction with hydrophobic regions of methyl-binding domains in various proteins.6 Because 
methylation of lysine residues does not affect the charge of the residue, this covalent modification 
can contribute to both transcriptional activation and repression. The position on the histone of the 
residue being modified, as well as surrounding residue modifications, determines whether the action 
will result in activation of transcription.  
Lys
N
4
O N
HO OH
N
N
N
NH2
S
CO2H
NH2
H
H
Lys
N
4
H
H
CH3
O N
HO OH
N
N
N
NH2
S
CO2H
NH2
+
S-adenosylmethionine S-adenosylhomocysteine  
Figure 1.5. Histone lysine methylation as carried out by SAM-dependent KMTs. 
Whereas the same histone can have multiple sites of modification, some histone marks 
prevent other histone modification events from taking place owing to what is known as histone 
crosstalk. For example, methylation of H3K9 is associated with the heterochromatin state, while 
methylation of H3K4 is associated with active gene expression. Studies show that these two 
modifications have an inverse relationship, whereby H3K9 cannot be methylated if H3K4 is 
methylated, and vice versa.16 Another example of histone crosstalk is found in the antagonistic 
relationship between H3R2 and H3K4; trimethylation of H3K4 prevents demethylation of H3R2, 
while dimethylation of H3R2 inhibits H3K4 methylation.17, 18  
 
6 
 
1.2  Dynamic Methylation and Demethylation of Histone 
Lysine Residues 
Histone lysine methylation is an interesting post-translational modification with integral roles 
in gene regulation, genomic integrity, and epigenetic inheritance. The C-N bond formed upon lysine 
methylation confers stability, which is critical to certain biological events, and interestingly, the mark 
is removable in response to stimuli, owing to the presence of histone lysine demethylases (HDMs). 
The role of histone methylation in epigenetic inheritance is not yet completely understood. Although 
research suggests that histone methylation is stable across generations, the inheritance of methyl 
groups on histones through cell divisions is a rare event, and the propagation of post-translational 
modifications of histones is an area of active study.19 One theory proposes the immediate 
modification of histones associating with newly synthesized DNA to maintain an epigenetic 
memory.20  
There exists a dynamic relationship between histone lysine methylation and demethylation 
that enriches the overall epigenetic regulatory system of the cell. Disruption to the activities of 
HMTs or HDMs has been shown to lead to aging, developmental defects, and cancer cell 
formation.19 There exist two classes of HDMs with distinct mechanisms of lysine demethylation: the 
amine-oxidase domain-containing HDMs, and the Jumonji C (JmjC)-domain containing HDMs. 
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1.3 Catalytic Mechanisms of  Histone Lysine Demethylation  
Although histone methylation was once believed to be a static modification, two classes of 
demethylases have been discovered that work through distinctly different mechanisms: the earlier 
discovered amine oxidase-domain containing, and a larger class of JmjC-domain containing, O2-
activating enzymes. The two classes of lysine demethylases are highly conserved from yeast to 
humans.19, 21  
1.3.1  Flavin-Dependent Histone Demethylases 
The earliest discovered class of HDMs includes just two members: LSD1 and LSD2 
(KDM1A and KDM1B). Demethylase activity is dependent on the amine-oxidase domain, and the 
cofactor flavin-adenine dinucleotide (FAD) is reduced in the demethylation reaction. KDM1A and B 
work through a mechanism that requires a lone electron pair on the lysine ε-nitrogen atom, as shown 
in Figure 1.6. Thus, the demethylase activity of KDM1A and KDM1B is limited to monomethylated 
lysine (Kme1) and dimethylated lysine (Kme2) residues.
22 After proceeding through iminium and 
hemiaminal intermediates, formaldehyde is released as a side product. Note that in Figure 1.6, only 
the flavin portion of FAD is shown.  
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Figure 1.6. Proposed mechanism of flavin-dependent HDMs.  
In the cell, formaldehyde that is produced from the demethylation reaction is continually 
oxidized as shown in Figure 1.7. Human formaldehyde dehydrogenase (FDH) is found in nearly 
every tissue of the body, and the enzyme works in conjunction with S-formylglutathione hydrolase 
to carry out the oxidation.  
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Figure 1.7. The oxidation of formaldehyde to formate. 
The histone lysine substrate-binding subdomain in the KDM1 enzymes is composed of 
multiple acidic residues that complement the basic histone tail.23 KDM1A is part of a protein 
complex named CoREST, and while in complex, the demethylase activity of KDM1A is specific for 
H3K4me2/1.
24, 25 Figure 1.8 shows how FAD is positioned for the hydride transfer from H3K4me2. 
Interestingly, when KDM1A associates with androgen receptor (AR), its specificity changes to 
H3K9me2.
26    
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Figure 1.8. A model of KDM1A (gray residues) in complex with H3K4me2 (green residues).
27  
1.3.2  Iron-Dependent Histone Demethylases 
Chemistry of the Iron Active Site 
JmjC-domain containing HDMs contain conserved N-terminal JmjC and JmjN catalytic 
domains, grouping the demethylases in the cupin superfamily of metalloenzymes.28 These 
demethylases are iron-dependent monooxygenases that utilize the cosubstrate α-ketoglutarate (αKG) 
for enzymatic activity. As shown in Figure 1.9, the active site iron in JmjC-HDMs coordinates to a 
conserved His2(Asp/Glu)1 facial triad. The remaining coordination sites are taken by an αKG analog 
and dioxygen, with the histone lysine substrate (H3K36me3) binding in a separate pocket.   
11 
 
 
Figure 1.9. The KDM4A active site, with iron coordinated to N-oxalylglycine and O2 (PDB 2P5B).
29 
Mechanism of Lysine Demethylation 
A six-coordinate Fe(II) is held in the enzyme active site through a conserved 2-histidine 1-
carboxylate binding motif (Figure 1.10).30 As shown through steady state kinetics experiments, αKG 
binds iron first in a bidentate fashion, displacing two H2O molecules. Next, an additional H2O 
molecule is lost as the histone lysine substrate binds in a pocket away from the iron center, resulting 
in a 5-coordinate Fe(II) species. Primary substrate binding facilitates the binding of O2 to the metal 
center, giving rise to an Fe(III)-superoxide radical. Superoxide acts as a nucleophile to attack the 
alpha-keto carbonyl of αKG, leading to rearrangement of a highly reactive Fe(IV)-oxo species.31 This 
species is responsible for hydroxylation of the primary substrate methyl group. Finally, the 
hydroxylated substrate converts non-enzymatically to the product. Side products of the reaction 
include formaldehyde, CO2, and succinate.  
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Figure 1.10. Mechanism of iron-dependent HDMs, where Lys-CH3 is the histone lysine substrate.  
 
Classification of JmjC-HDMs 
The 18 identified JmjC-HDMs have varying histone lysine substrate specificities and are 
grouped into five subfamilies: KDM2/7, KDM3, KDM4, KDM5, and KDM6 (Table 1.1). The 
focus of my research was on three members of the KDM4 subfamily: KDM4A, KDM4C, and the 
pseudogene-encoded KDM4E, as a substitute for KDM4D.  
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Table 1.1. JmjC-HDMs and their substrate specificities.32 
JmjC-HDM 
Subfamily 
Members Substrate Specificity 
 
KDM2/KDM7 
KDM2A 
KDM2B 
KDM7A 
PHF8 
H3K36me2/1, H3K4me3 
H3K36me2/1 
H3K27me2/1 
 
H3K9me2/1, H3K27me2/1,  
H3K36me2, H4K20me1 
KDM3 KDM3A, KDM3B 
KDM3C 
H3K9me2/1 
MDC1 at Lys4533 
KDM4 KDM4A, KDM4B, KDM4C 
KDM4D, KDM4E 
H3K9me3/2, H3K36me3/2 
H3K9me3/2 
KDM5 KDM5A, KDM5B, KDM5C, 
KDM5D  
H3K4me3/2 
KDM6 KDM6A, KDM6B H3K27me2/1 
 
Although the JmjC and JmjN domains are required for all JmjC-HDMs’ catalytic activity, 
only certain enzymes contain PHD and Tudor domains, which are proposed to have essential roles 
in enzymatic binding to chromatin.34-37 For instance, in the KDM4 subfamily, KDM4D lacks the 
PHD and Tudor domains, whereas KDM4A and KDM4C do not, and this difference may 
contribute to KDM4D being limited to a single substrate. Moreover, studies have shown KDM4C, 
and not KDM4A-B, to play a role in mitotic chromosome separation, and the Tudor domains of 
KDM4C are essential for its association with chromatin for this fidelity process.38  
The KDM4 subfamily contains five members: KDM4A-E, of which one (KDM4E) is 
encoded by a pseudogene, with the protein being catalytically active.34 KDM4 enzymes have putative 
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roles in a wide variety of cellular processes such as DNA replication, regulation of gene expression, 
and the DNA damage response.  
 
KDM4 Dual-Substrate Specificities 
Although one study has shown KDM4 enzymes to be capable of hydroxylating and de-
alkylating substrates other than Nε-methyl,39 KDM4 enzymes are highly selective, owing in large part 
to residues surrounding the methylated lysine of interest. Through competition experiments, it was 
found that KDM4A-C display highest catalytic activity toward H3K9 in the trimethylated state, but 
can also recognize H3K9me2. In addition, these enzymes act on H3K36me3/2, albeit at significantly 
lower rates. KDM4D-E activities are limited to H3K9me3/2.
34, 40  Crystal structures of KDM4A, C, 
and E have been obtained and reveal that these enzymes share remarkably similar active site 
structures, owing to highly conserved residues which make up the methylammonium-binding 
pocket. Because KDM4D/E cannot recognize H3K36, variants of KDM4A with residues thought 
to determine sequence selectivity in KDM4E were studied. None of the KDM4A variants studied 
displayed catalytic activity toward H3K36.34 
An octapeptide commonly used in in vitro studies of KDM4 enzymes includes a 
trimethylated lysine 9, and the sequence is as follows: ARK(me3)STGGK (H3(7-14)K9me3). Certain 
residues surrounding K9 on histone H3 have been found to be important for KDM4 recognition. 
Alanine at the -2 position was shown to be significant for peptide recognition by KDM4C, but not 
as important for KDM4A.41, 42 Serine at +1 and glycine at +3 are necessary for recognition by 
KDM4A, as the side chain of the former forms an intra-molecular hydrogen bond with the amide of 
the latter; interestingly, the Gly-Gly motif is not necessary for recognition by KDM4C.43 While their 
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H3 lysine specificities are the same, KDM4A and KDM4C differ in the length of H3K9 peptide 
necessary for recognition. KDM4A can demethylate an H3K9me3 peptide no shorter than eight 
residues (H3(7-14)K9me3), while KDM4C recognizes peptides as short as four residues                 
(H3(7-10)K9me3).
42  
1.4 HDMs in DNA Repair 
HDMs have been found to play important roles in the maintenance of genomic integrity.44-46 
Double-stranded breaks (DSB) in DNA lead to a coordinated cellular effort to recognize and repair 
the lesion efficiently, a process known as the DNA damage response (DDR). Recognition of lesions 
is done by Poly(ADP-ribose) polymerase (PARP) family proteins PARP1 and PARP2. If the DSB 
occurs in heterochromatin, decondensation of the chromatin is necessary.47 Rapid expansion of 
heterochromatin is characterized by displacement of HP1β from lesion sites without changes in 
H3K9 methylation status.48, 49  
Multiple HDMs have been found to be integral in the DDR. KDM1A has been implicated in 
the pathway, as H3K4 dimethylation is reduced at DNA lesion sites following irradiation in a 
KDM1A-dependent manner.46 At least two members of the KDM4 JmjC-HDM subfamily play 
putative roles in the maintenance of genomic integrity: KDM4B and KDM4D. One study found 
KDM4D to be recruited to lesion sites in a PARP1-dependent manner. Additionally, KDM4D is 
implicated in DSB repair, as the demethylase promotes the phosphorylation of early DNA damage 
markers such as checkpoint kinase 2 (CHK2).44 KDM4B overexpression has been found to improve 
the DDR by enhancing DSB repair following laser microirradiation.45 
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1.5 HDMs in Cancer 
It is widely known that inappropriate gene expression can lead to the development of 
disease. Chromatin modification is thought to contribute to the control of gene expression through 
influencing chromatin compaction or signaling to other protein complexes. One characteristic of 
tumors is the local and global changes in chromatin structure compared with healthy tissue, 
suggesting epigenetic deregulation as the culprit.50 Much research suggests that the regulation of 
histone methylation becomes askew in cancer, as well as in aging and intellectual disability.19, 51 
 
1.5.1  Flavin-Dependent Histone Demethylases 
Because KDM1A associates with both the functional corepressor complex CoREST and 
androgen receptor, this enzyme can act as a transcriptional co-repressor (by demethylating 
H3K4me2/1) or co-activator (by demethylating H3K9me2/1), depending on its association at the time. 
KDM1A is reported to be oncogenic and/or overexpressed in multiple cancers, including leukemias 
and solid tumors.52, 53 KDM1A is required for the maintenance of acute myeloid leukemia (AML)-
containing MLL translocations. Inhibition of KDM1A is found to significantly inhibit the colony-
forming ability of AML cells.54 In human prostate cancer cells, KDM1A cooperates with the JmjC-
HDM KDM4C to activate AR-mediated gene expression. KDM4C removes a methyl group from 
H3K9me3 at the promoter of AR target genes, while KDM1A finishes the demethylation of H3K9 
to activate transcription.55, 56 Mechanism-based inhibitors tranylcypromine and its derivatives have 
proven to be effective inhibitors of KDM1A, as they form adducts with FAD, and, thus, prevent 
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amine-oxidase activity of the enzyme (Figure 1.11). Tranylcypromine was first identified as a 
monoamine oxidase inhibitor (MAOI) for the treatment of depression.   
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Figure 1.11. Tranylcypromine (left) and a tranylcypromine-FAD adduct (right).57 
1.5.2  Iron-Dependent Histone Demethylases 
KDM4C is the KDM4 subfamily member implicated in the greatest number of cancers. 
KDM4C is a hypoxia-inducible factor 1 (HIF-1) target gene, which may explain KDM4C’s mRNA 
and protein overexpression in breast and colon cancers, medulloblastoma, and squamous cell 
carcinoma.58-60 HIF target gene products play putative roles in various steps of cancer progression.61 
In addition to working in concert with KDM1A to stimulate AR- mediated gene expression in 
human prostate cancer cells, KDM4C demethylates H3K9me3 at hypoxia response elements (HREs) 
of HIF-1 target genes, which enhances HIF-1 binding to HREs, promoting transcription.62 
Interestingly, increased KDM4C mRNA expression is linked to elevated tumor grade in human 
breast cancers.62  
KDM4A has been found to be overexpressed at the protein level in lung cancer, prostate 
cancer, and about 60% of breast tumors.63, 64 However, overexpression of KDM4A does not 
enhance tumor growth in all cancers, as studies of KDM4A in HeLa cervical carcinoma or 293T 
embryonal kidney cells have shown.65 In certain cell lines, overexpression of KDM4A reduces 
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recruitment and/or binding of HP1 to chromatin, as HP1 localizes upon trimethylation of H3K9.66 
Recent studies detail the complicated and cell line-specific nature of JmjC-HDM involvement in 
cancer. For instance, H3K9 trimethylation was found to be increased in certain breast and colon 
cancer cell lines during hypoxia.67  This recent finding may be partly explained by the low apparent 
affinity of KDM4 enzymes for O2 in vitro, with O2 Km values ranging from 60 – 200 µM, far above 
the cellular concentration of O2 during times of hypoxia.
68 Human breast cancers have intratumoral 
hypoxic regions with median pO2 values of 5 -10 mm Hg (<1.5% or ~10 - 20 µM O2), compared 
with ~ 35 mm Hg O2 in normal breast tissue.
62, 69 
 Whereas the inhibition of KDM1A has proven to be fairly straightforward, the inhibition of 
JmjC-HDMs is complicated by several factors. First, these enzymes share an active-site motif with a 
much larger group of enzymes, making selective inhibition difficult. Second, primary substrate 
selectivities stem from multiple main-chain interactions of the histone with the HDM. Lastly, of the 
three JmjC-HDM substrates, αKG is the highest affinity. However, designing inhibitors that bind 
like αKG is less than ideal owing to the promiscuous nature of such metal-binding compounds. 
Thus far, only two compounds have been identified that act as specific inhibitors of JmjC-HDMs 
without competing with αKG (Figure 1.12).70, 71  
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Figure 1.12. Two specific inhibitors of JmjC-HDMs. 
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1.6  Project Goals 
At the start of this dissertation work, the kinetics of the JmjC-HDM KDM4 subfamily had 
not been fully elucidated. Moreover, very little was known of the enzymology of KDM4C, an 
enzyme encoded by a putative oncogene, with the protein implicated in multiple cancers.62, 72-74 An 
early goal of this dissertation work was to gain a thorough understanding of the in vitro kinetics of 
three JmjC-HDMs with respect to all three substrates: a histone lysine substrate analog              
(H3(7-14)K9me3) and the two cosubstrates O2 and αKG. As the concentration of O2 in healthy cells 
and cancerous cells is dramatically different, it was of particular interest to determine how the 
KDM4 enzymes behave toward O2 in vitro.  
The second goal of this dissertation work was the development of a continuous, real-time in 
vitro enzymatic assay to study the activity of JmjC-HDMs. At the beginning of this work, the only 
published in vitro assays were discontinuous or coupled in nature, which can lead to distorted Km, 
kcat, Ki, and IC50 values.  
The final goal of this work was broad in scope: the development of small molecule inhibitors 
of JmjC-HDMs. As these enzymes are part of a much larger group of αKG-dependent oxygenases, 
the problem of target selectivity arises when designing inhibitors. At the time of this writing, only 
two of the hundreds of published JmjC-HDM inhibitors have been shown to selectively inhibit 
JmjC-HDMs without an αKG analog chelating the metal center.70, 71 This work describes two HDM 
inhibition strategies: the first, simple substrate analogs bearing di- or tri-methylammonium groups or 
analogs that include an amide oxalyl group; the second, a peptidomimetic approach to achieve 
isoform selectivity.  
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Chapter 2: Kinetic Analysis of  Iron-Dependent 
Histone Demethylases: α-Ketoglutarate Substrate 
Inhibition and Potential Relevance to the Regulation 
of  Histone Demethylation in Cancer Cells 
A portion of  this work was published as a communication in Biochemistry on October 15, 2012. 
DOI:10.1021/bi3012466 
2.1  Introduction 
 Covalent modification of  chromatin by histone methylation has wide-ranging effects on 
nuclear functions, such as transcriptional regulation, genome integrity, and epigenetic inheritance.1-3 
Until recently, histone methylation was believed to be a static modification, however the 
identification of  histone demethylase (HDM) enzymes has revealed that this epigenetic mark is 
dynamically controlled.4-6 The Jumonji C domain-containing HDMs (JmjC-HDMs) catalyze the 
demethylation of  methylated lysine residues through a hydroxylation reaction and belong to the large 
class of  α-ketoglutarate (αKG) dependent, O2-activating, non-heme iron enzymes.
7-9 To date, 18 
JmjC-HDMs have been reported and grouped into five subfamilies, and the enzymes exhibit both 
residue and methylation state specificity.10-12 In addition, JmjC-HDMs have been implicated in cancer 
and stem cell biology. For example, it has recently been shown that PLU-1 (KDM5B/JARID1B) is 
an H3K4 HDM that plays an important role in the proliferation of  breast cancer cells through 
transcriptional repression of  tumor suppressor genes,13, 14 while the H3K9/H3K36 HDM GASC1 
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(or KDM4C/JMJD2C) was proposed to be linked to stem-cell phenotypes in breast cancer.15 Thus, 
it is of  great interest to design specific inhibitors for the various HDM subfamilies by utilizing the 
enzymes’ substrate specificities.16-24 However, there is limited data available on the enzymology of  
HDMs. In this regard, we have successfully expressed and purified three HDMs of  the KDM4 
subfamily, including cancer-relevant KDM4A and KDM4C, and obtained a detailed enzyme kinetic 
analysis by employing three different assays (vide infra). Interestingly, a case of  αKG substrate 
inhibition was observed, which could have important implications into the regulation of  KDM4 
activity in cancer biology. 
2.2  Methods  
2.2.1  Protein Expression and Purification 
Truncated constructs of KDM4A,11  KDM4E,11 and KDM4C,19  containing the catalytic 
JmjC- and JmjN- domains, were obtained as gifts from Professors Schofield and Opperman 
(KDM4A and KDM4E) and Professor Mizukami (KDM4C), and were expressed and purified as 
reported,11, 19 with minor modifications. Each plasmid was transformed into the Rosetta II (DE3) 
strain of E. coli, with colonies grown on LB agar + kanamycin (KM) plates.  Single colonies were 
picked and allowed to grow overnight in Terrific Broth (TB) medium supplemented with 50 μg/mL 
KM and 34 μg/mL chloramphenicol (CAM).  The overnight culture was split evenly into four flasks 
containing 600 mL TB with the appropriate antibiotics and 0.4% glycerol, and the inoculation was 
set to shake at 225 rpm at 37 °C.  When the absorbance at 600 nm reached 0.5, the temperature was 
reduced to 18 °C.  When OD600 = 0.8, expression was induced with 0.2 mM IPTG, and the growth 
was continued for 18 hours at 18 °C, at which time the cells were collected via centrifugation (3500 
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rpm for 20 minutes, 4 °C) and lysed.  Lysis conditions: 50 mM HEPES (pH 7.5), 500 mM NaCl, 5 mM 
imidazole, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM tris(2-carboxyethyl)phosphine 
(TCEP), 15 units/mL benzonase.   
Following lysis, the cells were sonicated in 30 second intervals for approximately 30 min.  
The homogenized cells were spun at 10,000 rpm for 30 min at 4 °C, and the supernatant was 
collected and purified over a Ni-NTA superflow column using increasing concentrations of 
imidazole.  The elution fractions rich in the protein of interest were exchanged into 50 mM Tris (pH 
8.5) with 50 mM NaCl overnight.  The protein solution was passed over 1 mL anion-exchange resin 
(Super-Q, Bio-Rad) using a step gradient of increasing concentrations of NaCl. Fractions of interest 
were combined and exchanged into a storage buffer (500 mM NaCl, 10 mM HEPES pH 7.5, 500 
μM TCEP, 5% glycerol), concentrated, and flash frozen in liquid nitrogen.  The yield of !95% pure 
protein (Figure 2.1) varied from 3 mg/L (KDM4C) to 20 mg/L (KDM4E).  
 
Figure 2.1. Coomassie Blue stained 4-20% SDS-PAGE gel of (left to right): MW marker (kDa) and 
purified KDM4A, KDM4E, and KDM4C. 
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2.2.2  Formaldehyde Dehydrogenase Coupled Fluorescence Assay  
 
Scheme 2.1. Oxidation of formaldehyde is coupled with the reduction of NAD+.  
 
H H
O
FDH from P. putida
H2O + NAD
+ NADH + 2H+
H O-
O
 
 
 
 
All reactions were performed at room temperature. The fixed assay conditions were 50 mM 
HEPES (pH 7.5), 500 μM sodium L-ascorbate, 50 mM NaCl, 0.04 units formaldehyde 
dehydrogenase (FDH) (P. putida, Sigma), and 1 mM NAD+. In H3(7-14)K9me3 variation assays       
(25-750 μM), αKG was held constant at 300 μM. In αKG variation assays (10-5000 μM),            
H3(7-14)K9me3 was held constant at 250 μM. All FDH coupled assays were performed at 258 μM O2 
concentration. The reaction components (except H3(7-14)K9me3) were combined and added to a 
mixture of 50 μM FeII(NH4)2SO4·6H2O and 8 μM HDM. The reaction was started by addition of 
H3(7-14)K9me3 and fluorescence of NADH production was monitored for 10 minutes.  In order to 
eliminate the possibility of artificially enhanced enzymatic activity due to uncoupling, the extent of 
demethylation of the peptide substrate was confirmed by MALDI-TOF MS (section 2.2.4). The 
apparent kinetic parameters kcat and Km were determined by fitting the kinetic data to the Michaelis-
Menten equation (2-1) by using the program Kaleidagraph: 
rate  
 max S 
Km   S 
  (2-1) 
 The apparent Ki values for αKG were determined by fitting the kinetic data to the following 
substrate inhibition equation (2-2) using the program Kaleidagraph: 
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rate   
 max S 
Km
1 
 S 
Km
 
 S 2
KmKi
  (2-2) 
 Although NAD+ shows no inhibition of KDM4E up to 3 mM, the higher Km(peptide) and 
lower kcat values obtained through the FDH coupled assay (vide infra) are likely due to the less-than-
optimal activity of P. putida FDH at high peptide concentrations, when a lag phase in NADH 
formation was observed. A lag phase in the formation of NADH was when the initial HDM initial 
rates were large (e.g., at high peptide substrate concentrations, Fig. 2.3). This could be due to either a 
less-than-optimal enzymatic rate for the FDH-catalyzed reaction that is lower than the HDM 
enzymatic rate, or a partial inhibition of FDH by the excess peptide. Overall, the observed lag phase 
could lead to overestimated Km values and underestimated kcat values, as observed experimentally 
(see Table 2.1). In addition, although slightly higher enzymatic HDM activities were observed at 37 
°C and pH 8 vs. 25 °C and pH 7.5, we employed the latter conditions to allow a direct comparison 
with literature data.  


 
Figure 2.2. Observed lag phase in NADH formation at high peptide substrate concentrations. 
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2.2.3  Dioxygen Consumption Assay 
All reactions were performed at 25 °C. A YSI model 5300 biological oxygen electrode was 
used to measure the initial rates of oxygen uptake, which were found to be linear for approximately 
2 min. The instrument was calibrated by using air-saturated water, which contains 258 μM O2 and 
was assigned to correspond to “100% Air”. The fixed assay conditions include 50 mM HEPES pH 
7.5 (or 50 mM Tris pH 7.5) and 500 μM sodium L-ascorbate. The HDM concentration ranged from 
1.6 to 3.0 μM, as given in Figures 2.4 and 2.5. In H3(7-14)K9me3 variation assays (5-500 μM), αKG 
was held constant at 300 μM. In αKG variation assays (2-6000 μM), H3(7-14)K9me3 was held constant 
at 100 μM. In O2 variation experiments (15-1200 μM), the H3(7-14)K9me3 and αKG were held 
constant at 100-250 μM and 300 μM, respectively. The reaction mixture was allowed to equilibrate in 
the electrode chamber under an atmosphere containing various amounts of O2. The reaction was 
started by addition of the HDM enzyme reconstituted with 1 equivalent FeII(NH4)2SO4·6H2O to the 
O2 electrode chamber. All rates were calculated subtracting background oxygen consumption due to 
ascorbate and/or Fe(II) in the absence of enzyme. Normally, these background rates of O2 
consumption due to the presence of both Fe(II) and ascorbate are negligible (less than 1%) vs. the 
typically measured enzymatic rates for HDMs. In addition, a similar negligible O2 consumption 
background rate was observed in the presence of the holoenzyme and the absence of the peptide 
substrate, suggesting a very limited extent of enzyme uncoupling. The apparent kinetic parameters 
kcat and Km were determined by fitting the kinetic data to the Michaelis-Menten equation (2-1) using 
the program Kaleidagraph. 
The apparent Ki values for αKG were determined by fitting the kinetic data to the substrate 
inhibition equation (2-2) using the program Kaleidagraph. 
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To eliminate the possibility of artificially enhanced enzymatic activity due to uncoupling, the 
extent of demethylation of the peptide substrate was confirmed by MALDI-TOF MS (see Section 
2.2.4). 
2.2.4  MALDI-TOF Mass Spectrometry Assay 
 In a typical assay, the purified HDM (8 μM) was incubated for 10 min at 37 °C with        
H3(7-14)K9me3 (80-250 μM) in 50 mM HEPES (pH 7.5), 50 μM Fe
II(NH4)2SO4·6H2O, 500 μM 
sodium L-ascorbate, and varying αKG (50 μM, 100 μM, 300 μM, 1 mM, 3 mM, 5mM). The 
enzymatic demethylation was stopped by addition of  MeOH and TFA, the precipitated protein was 
removed via centrifugation, and the resulting supernatant was collected. An aliquot of  the reaction 
solution was added to 10 mg/mL α-cyano-4-hydroxycinnamic acid MALDI matrix in 50% 
acetonitrile/0.1% TFA and spotted directly onto the MALDI plate. For analysis, an ABI DE-STR 
MALDI TOF instrument was used.  
 In addition, MALDI-TOF MS assays were used to confirm the extent of  demethylation of  
the peptide substrate for the FDH coupled assay or O2 consumption assay experiments. MALDI-
TOF MS studies were performed at both 37 °C and 25 °C, and the results were similar, except that 
the reaction was slower at 25 °C, and led to smaller amounts of  demethylated product that were 
more difficult to quantify accurately. Thus, we chose to use the 37 °C data for confirming the αKG 
substrate inhibition behavior. 
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2.2.5  Docking Studies of  KDM4A and KDM4C with αKG 
Low energy conformers of αKG were generated using OMEGA following minimization by 
SZYBKI (both OpenEye software). The conformers were modeled into the KDM4A (PDB 2OQ7) 
and KDM4C (PDB 2XML) active sites with OpenEye’s FRED fast exhaustive docking program 
using the Poisson-Boltzmann solvation method at 310 K, taking into account cavity solvation 
energies. All renderings were generated using PyMol.  
 
2.2.6  Crystallography 
Protein crystals were grown by the hanging drop vapor diffusion method at 4 °C. Crystals of 
the catalytic domains of KDM4A (residues 1-350; 11 mg/mL) in complex with αKG (100 mM) 
formed in drops of a 1 : 1.5 mixture of protein and crystallization buffer (0.1 M citrate pH 6.0, 
17.5% PEG-3500, 4 mM NiCl2). Crystals were harvested from the mother liquor with a nylon loop, 
mounted on a goniometer, and directly frozen in a liquid N2 vapor stream at 100 K.  Data were 
collected by Dr. Soon Goo Lee using 19ID beamline at Argonne National Laboratory Advanced 
Photon Source with a CCD detector at a distance of 361.69 mm from the crystal.  Images (180 
frames) were collected at 0.979 Å in 1.0°oscillations (a 180° hemisphere) indexed (P 2 21 21) and 
scaled using HKL 3000.25  This resulted in 50,379 reflections in the 50 - 2.1 Å resolution range. Unit 
cell parameters and data reduction statistics are summarized in Table A.1 in Appendix A.  
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Detector CCD 
Type ADSC QUANTUM 315r 
Details Rosenbaum-Rock high-resolution double-crystal monochromator 
 
The structure of KDM4A was phased by using the molecular replacement method with 
Phaser, and a model of the crystal structure of KDM4A complexed with inhibitor (PDB: 3RVH) 
structure.26  Based on the Matthew’s coefficient, two protein monomers were expected in the 
asymmetric unit.  The solution from Phaser had a top TFZ of 41.6. Manual fitting was initiated 
using COOT.27 Refinement was performed using Phenix with 10% of the data excluded from 
refinement for the Rfree calculation.
28 The structure models were analyzed at TLS Motion 
Determination Server and refined with eight TLS groups, yielding a model with an Rcryst of 18.1% and 
Rfree of 22.4%.
29 The final model was analyzed by using the CCP4 programs SFCHECK and 
PROCHECK.30, 31, 32 Refinement statistics are listed in Table A.1 in Appendix A.  
 
2.3  Results and Discussion 
 In the lysine demethylation reaction, JmjC-HDMs hydroxylate the N-methyl substrate to a 
hydroxymethyl group, which is converted non-enzymatically to formaldehyde and the demethylated 
product (Scheme 1).4-6 Our initial kinetic studies focused on KDM4A, the first HDM with a resolved 
crystal structure and one that has been used extensively in biochemical studies.10-12 Moreover, 
KDM4A was recently found to be overexpressed at the protein level in lung cancer, prostate cancer, 
37 
 
and about 60% of  breast tumors.15, 33, 34 The pseudogene-encoded KDM4E, which shares greater 
than 80% sequence similarity to KDM4A, has been often employed in enzyme activity studies as it 
has the highest activity when compared to the other members of  the KDM4 subfamily.16-24 Finally, 
KDM4C is of  great interest owing to its implications in brain, breast, prostate, and esophageal 
cancers,15, 35 although the kinetics of  KDM4C has not been fully investigated to date.16-24 
 
Scheme 2.2. Histone demethylation by JmjC-HDMs, shown for a trimethyllysine substrate. 
a. Overview of lysine demethylation 
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b. Proposed mechanism of lysine demethylation 
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 Truncated constructs of  KDM4A,10-12 KDM4E,16-24 and KDM4C,16-24 containing the catalytic 
JmjN- and JmjC- domains, were transformed into the E. coli Rosetta II strain and expressed and 
purified using published procedures (see Section 2.2.1). The enzymatic activity of  the three HDMs 
was monitored by three complimentary assays: a coupled formaldehyde dehydrogenase (FDH) 
NADH fluorescence assay, a discontinuous MALDI-TOF mass spectrometry (MS) assay, and a 
continuous O2 consumption assay. Initially, kinetic parameters were obtained using an adapted 
version of  the widely-employed FDH coupled assay,10-12, 36, 37 and a trimethylated H3(7-14)K9me3 
octapeptide as the histone substrate analog. However, this coupled assay could yield altered kinetic 
data owing to the employment of  a second enzyme and corresponding substrate in the reaction 
solution (vide infra). Demethylation of  the peptide substrate was also confirmed by MALDI-TOF 
MS, and quantification of  the amount of  di- and mono-methylated peptide products was correlated 
to the extent of  demethylation measured using the other enzymatic assays. However, no direct 
continuous assay to study the enzymatic activity of  HDMs has been developed to date. In this 
regard, we have employed a continuous O2 consumption assay that measures in real-time the HDM 
enzymatic activity through the use of  a Clark oxygen electrode. To the best of  our knowledge, this is 
the first kinetic study of  HDMs using a continuous O2 consumption assay, which could provide 
more physiologically relevant kinetic parameters.38  
 Using the above enzyme activity assays, we determined the kinetic parameters for three 
JmjC-HDMs with respect to all three substrates: the H3(7-14)K9me3 peptide substrate, O2, and αKG. 
For KDM4A and KDM4C, the FDH-coupled assay yielded Km values for the peptide substrate   
(104 ± 16 μM for KDM4A, 76 ± 11 μM for KDM4C) that are similar to those found in the 
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literature,10-12, 16-24, 39, 40 while for KDM4E a slightly larger Km value was obtained (224 ± 15 μM, Table 
2.1).
1
  Figure 2.3 displays the H3(7-14)K9me3 Km plots for the three HDMs.  






 
Figure 2.3. Variable H3(7-14)K9me3 Km plots obtained using the FDH-coupled assay. 
 
Interestingly, the use of  the O2 consumption assay reveals significantly reduced peptide Km 
values for KDM4A (31 ± 3 μM), KDM4C (32 ± 3 μM), and KDM4E (38 ± 3 μM), as well as 
turnover numbers that are similar or higher than those from other studies (Figure 2.4).10-12, 16-24, 39, 40 
The O2 consumption assay can be performed under saturating conditions for all substrates, and, 
thus, it provides a unique opportunity to obtain true kcat values for the three HDMs (Table 2.1). 
Most importantly, the observed activity of  KDM4C is higher than reported previously,16-24 and 
comparable to the activities of  KDM4A and KDM4E, the HDMs commonly employed in enzyme 
activity studies.16-24 Thus, KDM4C can now be used in inhibition studies employing the O2 
consumption assay, especially given its direct implication in cancer biology.15 Overall, the O2 
consumption assay seems to allow for a superior characterization of  HDMs vs. the FDH coupled 
                                                 
1 While NAD+ shows no inhibition of KDM4E up to 3 mM, the higher Km(peptide) values obtained through 
the FDH coupled assay are likely due to the presence of a second enzyme and corresponding substrate in the 
reaction solution. 
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assay, because the obtained Km values for the peptide substrate are more in line with the expected 
affinities for the natural substrate in vivo, whereas higher turnover numbers were also found for all 
three HDMs investigated.  
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Figure 2.4. Variable H3(7-14)K9me3 Km plots obtained from the O2 consumption assay for               
1.6 μM KDM4A, 3 μM KDM4C, and 2.1 μM KDM4E. 
 
Table 2.1. Kinetic parameters for the three JmjC-HDMs with respect to the primary histone analog 
substrate.a 
HDM Assay 
H3(7-14)K9me3 
Km
app(μM) 
 
kcat
app (min-1)b 
KDM4A 
O2 consumed 31 ± 3 2.5 ± 0.1 
coupled FDH 104 ± 16 1.4 ± 0.1 
KDM4C 
O2 consumed 32 ± 3 2.1 ± 0.1 
coupled FDH 76 ± 11  0.70 ± 0.03 
KDM4E 
O2 consumed 38 ± 3 3.3 ± 0.1 
coupled FDH 224 ± 15 2.1 ± 0.1 
a See section 2.2 for assay conditions. b kcat
app values were determined at 258 μM O2. 
 Though the majority of  HDM inhibitors reported are αKG analogs,16-24 it may be desirable 
to design inhibitors that compete in the enzyme active site not just with respect to αKG, but also 
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with respect to the peptide substrate or O2. Using the O2 consumption assay, we measured for the 
first time the Km(O2) values for HDMs and found that these enzymes have relatively low apparent 
affinities for O2, with Km values near or above normal cellular O2 concentration (57 ± 10 μM for 
KDM4A; 158 ± 13 μM for KDM4C; 197 ± 16 μM for KDM4E; Figure 2.5 and Table 2.2).41 Such 
O2 affinities suggest the enzymatic activity can be altered by small changes in O2 concentration, and, 
thus, the JmjC-HDMs can act as oxygen sensors in vivo, as observed previously for other αKG-
dependent non-heme iron oxygenases involved in the hypoxic response.41 
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Figure 2.5. Variable O2 Km plots obtained using the O2 electrode assay for 2 μM KDM4A, 3 μM KDM4C, 
and 2.1 μM KDM4E. 
 
Table 2.2. Kinetic parameters for the three JmjC-HDMs with respect to the secondary substrate O2.
a 
HDM Assay 
O2 
Km
app(μM) 
 
kcat
app (min-1) 
KDM4A O2 consumed 57 ± 10 2.5 ± 0.1 
KDM4C O2 consumed 158 ± 13 2.6 ± 0.1 
KDM4E O2 consumed 197 ± 16 4.0 ± 0.1 
a See section 2.2 for assay conditions. 
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Contrastingly, the enzymes’ affinities for αKG are high compared to those for O2, and in line 
with values reported previously.16-24, 42, 43 For all three HDMs investigated, the αKG Km values are 
between 10 and 37 μM and differ by less than two-fold between the FDH coupled assay and the O2 
consumption assay, with the latter technique providing slightly lower Km values (Table 2.3).   
Table 2.3. Kinetic parameters for the three JmjC-HDMs with respect to the secondary substrate 
αKG.a 
HDM Assay 
αKG 
Km
app(μM) 
 
Ki
app (mM)b 
KDM4A 
O2 consumed 10 ± 1 10 ± 2 
coupled FDH 21 ± 4 13 ± 3 
KDM4C 
O2 consumed 12 ± 2 4.3 ± 0.6 
coupled FDH 22 ± 5 3.4 ± 0.6 
KDM4E 
O2 consumed 21 ± 2 12 ± 1 
coupled FDH 37 ± 7 11 ± 3 
a See section 2.2 for assay conditions. b αKG Ki
app values reported at 258 μM O2. 
 
 While investigating the affinities of  KDM4A and KDM4E for αKG, we found a mild 
substrate inhibition effect when αKG was present in high concentrations (>1 mM; the plots for 
KDM4A and KDM4E are given in Figure 2.6). The apparent Ki values were obtained using the 
FDH coupled assay (KDM4A, Ki
app = 13 ± 3 mM; KDM4E, Ki
app = 11 ± 3 mM) and the O2 
consumption assay (KDM4A, Ki
app = 10 ± 2 mM; KDM4E, Ki
app = 12 ± 1 mM, Table 2.3).  
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Figure 2.6.  ariable αKG Km plots obtained for a) KDM4A and b) KDM4E using the (left) O2 
consumption and (right) FDH coupled assays. 
  
Interestingly, the αKG inhibitory effect is significantly stronger in the case of  KDM4C 
(FDH coupled assay: Ki
app = 3.4 ± 0.6 mM; O2 electrode assay: Ki
app = 4.3 ± 0.6 mM; Figure 2.7). Of  
note is that succinate, the product derived from αKG decarboxylation, was found to have no 
inhibitory effect on KDM4C up to 1mM. In addition, the variation of  ionic strength (0 vs. 50 mM 
NaCl) or buffer (Tris vs. HEPES) has only a negligible effect on the measured enzymatic rates. 
Overall, these results suggest that the observed αKG substrate inhibition behavior is likely not due 
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to a generic ion or ionic strength effect. Moreover, the inhibition of  KDM4C by αKG was 
confirmed by MALDI-TOF MS analysis (Figure A.1, Appendix A).  




 




 
Figure 2.7. Inhibition of  KDM4C by αKG, as measured by the (left) O2 consumption and (right) 
FDH coupled assays. For reaction conditions, see section 2.2. 
 
 Although previous studies reported the inhibition of  other αKG-dependent Fe(II) 
oxygenases by αKG,44-46 the type of  inhibition with respect to the other substrates was not 
investigated in detail. In this regard, the inhibition of  KDM4C by αKG was measured at constant 
αKG concentrations (300 μM, 2 mM, 4 mM, 5 mM) and variable O2 concentrations by using the O2 
consumption assay. It was found that the Km value for O2 increased with increasing αKG 
concentration, while the Vmax value stayed relatively constant (Figure 2.8).  
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Figure 2.8. Variable O2 Km plots for 3 μM KDM4C obtained at varying at αKG concentrations. For 
reaction conditions, see section 2.2. 
 
In addition, a double reciprocal plot of  the inverse of  rate of  reaction vs. the inverse of  O2 
concentration reveals that the linear plots corresponding to the different αKG concentrations 
intersect on the y-axis, suggesting that αKG is a competitive inhibitor with respect to O2 (Figure 
2.9). Importantly, a competitive inhibition of  O2 by αKG has not been observed for any αKG-
dependent oxygenase to date.16-24, 44-46 Moreover, the more pronounced αKG inhibition of  KDM4C 
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vs. KDM4A and KDM4E is expected to impact the different activity profiles in vivo for these 
enzymes.  
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Figure 2.9. Double reciprocal plot of  1/rate of  O2 consumed vs. 1/[O2] obtained using the O2 
consumption assay, suggesting αKG competitive inhibition of  KDM4C with respect to O2. 
  
To test the mode of  αKG inhibition of  KDM4C with respect to H3(7-14)K9me3,               
H3(7-14)K9me3 Km plots were generated at 300 µM, 2 mM, and 5 mM αKG concentrations by using 
both the FDH-coupled and O2 consumption assays. From the FDH-coupled assay double-reciprocal 
plot shown in Figure 2.10, we find that αKG shows a weak, mixed-mode nonlinear inhibition of  
KDM4C with respect to the histone analog substrate.47, 48 Such a mode of  inhibition is as expected, 
because the peptide substrate does not interact directly with the metal center and binds in the active 
site in a different pocket than O2 and αKG.  
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Figure 2.10. Variable H3(7-14)K9me3 Km plots obtained using the FDH-coupled assay for KDM4C at 
αKG concentrations of  300 µM, 2 mM, and 5 mM, and double reciprocal plots for KDM4C 
inhibition by αKG with respect to H3K9me3, showing a mixed-mode, nonlinear type of  inhibition 
(bottom). 
  
When the mode of  αKG inhibition of  KDM4C with respect to H3(7-14)K9me3 was tested 
using the O2 consumption assay, results similar to those from the FDH coupled assay were obtained. 
Although there is a modest increase in the apparent Km as the αKG concentration increased, we find 
from the double reciprocal plots that the intersection does not occur on the y-axis, thus displaying a 
mixed-mode type of  inhibition as expected (Figure 2.11).47, 48 
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Figure 2.11. Variable H3(7-14)K9me3 Km plots obtained using the O2 electrode assay for 3 μM 
KDM4C at αKG concentrations of  300 µM, 2 mM, and 5 mM, and double reciprocal plots for 
KDM4C inhibition by αKG with respect to H3K9me3, showing a mixed-mode, nonlinear type of  
inhibition (bottom). 
 
The observed αKG substrate inhibition of  KDM4C could have important implications in 
cancer biology, as KDM4C is encoded by the putative oncogene GASC1 that is implicated in various 
types of  cancer.35 In normal healthy cells, the expression and activity of  KDM4C is believed to be 
highly regulated.15, 35 Given the observed in vitro inhibition by αKG, the activity of  KDM4C could 
be regulated in healthy tissue through a high cellular concentration of  αKG, which does not allow 
for an optimal demethylase activity of  KDM4C. Interestingly, there is a large difference in the level 
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of  αKG in healthy brain cells and glioblastomas. Whereas in healthy brain tissue the αKG 
concentration ranges from 1 to 3 mM,49 it has been reported that the αKG concentration in gliomas 
and glioblastoma multiformes is 100-300 μM.50, 51 Indeed, we find that KDM4C displays its highest 
activity in vitro at an αKG concentration of  ~300 μM (Figure 2.12), suggesting that a decreased 
concentration of  αKG could lead to an increased HDM activity in cancer vs. normal cells.52  
 
Figure 2.12. The activity of  KDM4C is optimized at 300 µM αKG in vitro. 
Crystal structures of  KDM4A and KDM4C in complex with Ni2+ and N-oxalylglycine were 
used in docking studies to visualize how a second molecule of  αKG might potentially fit into the 
two active sites (Figure 2.13). We find a lower overall score or more energetically favorable fit for the 
second αKG in the KDM4C active site vs. the KDM4A active site. 
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Figure 2.13. Docking studies of  N-oxalylglycine (green) and αKG (blue) in the active sites of  (left) 
KDM4A (PDB 2OQ7) and (right) KDM4C (PDB 2XML). 
  
Interestingly, the orientation of  αKG is flipped in the two active sites, with the α-keto 
oxygen closer to the metal center in the KDM4C model. Unlike the known mode of  αKG binding, 
we find that the α-keto group of  the second αKG molecule is not predicted to chelate the metal 
center in the KDM4C active site (Figure 2.14, right). We find that αKG is modeled closer to the 
metal center in the KDM4A active site (Figure 2.14, left).   
51 
 
 
Figure 2.14. A comparison of  docked αKG – Ni(II) distances in the active sites of  KDM4A (left) 
and KDM4C (right); distances in Å.  
  
The predicted polar contacts that a second molecule of  αKG could make in each of  the 
KDM4 active sites are shown in Figure 2.15. In both models, the second molecule of  αKG is 
predicted to form a hydrogen bond with homologous serine and tyrosine residues (Ser 288 or 290, 
Tyr 177 or 179). However, only in the KDM4C is the second molecule of  αKG predicted to make 
additional contact with a lysine side chain NH3
+ group (Lys 243), as shown in Figure 2.15 (right). 
This additional stabilizing interaction contributes to the overall lower energy score we find when 
modeling the second molecule of  αKG in the KDM4C vs. KDM4A active sites. 
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Figure 2.15. The predicted polar contacts for a second molecule of  αKG in the active sites of  
KDM4A (left) and KDM4C (right).  
  
Finally, we attempted to obtain a crystal structure of  KDM4A in complex with two 
molecules of  αKG, despite the high Ki
app value obtained from both the coupled FDH and O2 
consumption assays (Table 2.3). Protein expression limitations prevented us from attempting to 
obtain the structure with KDM4C. Briefly, KDM4A (11 mg/mL, 262 µM) was incubated with NiCl2, 
PEG-3500, and 100 mM αKG in citrate buffer to generate crystals via the hanging drop diffusion 
method at 4 °C. Ni(II) is used in the crystallization, as it coordinates in place of  Fe(II) and prevents 
enzymatic activity. The resulting 2.10 Å data set obtained from a single crystal reveals KDM4A in 
complex with a single molecule of  αKG (Figure 2.16). As this binary complex has not been solved 
before, we can compare it to the published KDM4A-Ni-NOG 2.15 Å structure (Figure 2.17).  
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Figure 2.16. The experimental 2Fo ─ Fc electron density, displayed as blue mesh, is shown for the 
αKG ligand, which coordinates in a bidentate fashion to Ni(II) (substituting for Fe(II)).  
 
      
Figure 2.17. KDM4A in complex with Ni(II) and α-ketoglutarate (left) or N-oxalylglycine (right) 
(distances in Å; (left) unpublished structure, (right) PDB 2OQ7).  
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We find that the distances between the metal center and the facial triad (2 His, 1 Glu) are 
slightly different in the two complexes, while the Ni – NOG and Ni – αKG distances are the same.  
This is in contrast to what would be expected owing to the resonance of  NOG (Figure 2.18). From 
the resonance contribution, one might anticipate a stronger Ni – NOG interaction than Ni – αKG. 
Moreover, one might anticipate a weaker Ni – His interaction in the NOG complex, but instead we 
find the Ni – His276 interaction stronger than in the αKG complex.  
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Figure 2.18. Resonance of  N-oxalylglycine.  
2.4  Conclusions 
 In conclusion, a detailed kinetic analysis of  three JmjC-HDMs, including cancer-relevant 
KDM4A and KDM4C, was achieved by employing three enzyme activity assays. Using a continuous 
O2 consumption assay, we found that HDMs have affinities for O2 near or above the cellular O2 
concentration, suggesting that HDMs can act as oxygen sensors in vivo. Importantly, we have 
observed a case of  αKG substrate inhibition, and the kinetic data suggest that αKG inhibits 
KDM4C competitively with respect to O2. The concentration of  αKG at which KDM4C displays 
optimal activity in vitro is similar to the concentration of  αKG in cancer cells, which has direct 
implications for the increased activity of  KDM4C in cancer vs. normal cells. Future studies will 
focus on probing the effect of  αKG concentration on the activity of  HDMs in vivo, as well as the 
implication of  αKG concentration variation in the epigenetic control of  cancer vs. normal cells. 
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Lastly, a new KDM4A crystal structure was solved, with the protein in a binary complex with Ni(II) 
and αKG.  
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Chapter 3: Survey of  Simple Primary- and 
Secondary-Substrate Analog Inhibitors of  
Iron-Dependent Histone Demethylases 
 
3.1 Introduction 
Chromatin is composed of double stranded DNA wound around a histone protein core. 
Covalent modifications of chromatin are essential for epigenetic inheritance, regulation of 
transcription, and maintenance of genomic integrity.1-3 The JmjC-domain containing histone 
demethylases (JmjC-HDMs) are mononuclear non-heme Fe(II) oxygenases that remove methyl 
groups from lysine residues on the tails of histones through a hydroxylation reaction. The eighteen 
reported JmjC-HDMs display remarkable residue and methylation-state specificities despite their 
high sequence homology and common active site structure.4-6 Much research suggests that the 
regulation of histone methylation becomes askew in cancer, as well as in aging and intellectual 
disability.7-10 JmjC-HDMs are considered attractive therapeutic targets as their expression is often 
increased in primary tumors.11 For instance, three members of the KDM4 subfamily, KDM4A, B, 
and C, are found to be upregulated in breast tumors.12-14  
 Because JmjC-HDMs belong to the large α-ketoglutarate (αKG)-dependent oxygenase class 
of enzymes, selective inhibition of a subclass of JmjC-HDMs is remarkably difficult, as recent 
studies have shown.15-18 The majority of reported JmjC-HDM inhibitors are bidentate iron chelators 
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and thus, αKG competitors.19-21 Although some of these αKG analogs have shown degrees of 
subfamily and isoform selectivity, the most promising selective inhibitors compete with the primary 
histone substrate, such as the recently reported small molecules JIB-04 and Tripartin, a natural 
product (Figure 3.1).16, 17, 22 Although JIB-04 is a primary substrate competitor, some of its inhibitory 
power comes from an interaction with the enzyme active site metal center.  
 
N
N
HN
N
Cl
JIB-04
HO
OH
O
Cl
ClHO
Tripartin  
Figure 3.1. Two primary-substrate competitors of JmjC-HDMs. 
 
The Fe(II) center in the JmjC-HDM active site is bound by a common structural motif, the 
His2Asp/Glu1 facial triad, with the three remaining positions of the octahedron taken by H2O 
molecules. αKG binding displaces two waters, prompting primary substrate binding in a separate 
pocket and formation of a five-coordinate Fe(II). Finally, O2 binds iron, is cleaved, and the resultant 
Fe(IV)-oxo reacts with the Nε-methyl group of the lysine substrate to form an unstable hemiaminal 
(Figure 3.2).23 
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Figure 3.2. Catalytic mechanism of JmjC-HDMs.  
 
 We are interested in designing inhibitors that compete for the axial O2-binding spot on iron 
in the JmjC-HDM active site. Recently, members of the KDM4 subfamily were found to display low 
apparent affinities for O2 in vitro, making O2 competitors interesting potential therapeutic targets.
24 
An early area of interest in this work revolved around whether members of the KDM4 subfamily 
could act as reaction vessels in enzyme-templated Huisgen 1,3-dipolar cycloaddition reactions 
between enzyme – metal – azide complexes and alkyne-containing substrates (Scheme 3.1). Azide 
(N3
-) has been shown to bind ferrous iron in a manner similar to dixoygen in a number of heme and 
non-heme iron enzymes.25-28 In this inhibitor design scheme, the HDM acts as its own specific-
inhibitor synthesizer. Any formed triazole-containing compounds could be synthesized 
independently and tested as inhibitors of JmjC-HDMs. 1,2,3-Triazole would be expected to bind the 
metal center similarly as azide, albeit in a stronger manner.  
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Scheme 3.1. In situ HDM-templated click-chemistry 
Glu
Fe N3
His
His
HDM-azide adduct
Glu
Fe N
His
His N N
In situ triazole formation
Denature
N N
NH
Detect by ESI-MS 
 
We designed simple KDM4 substrate analogs bearing carbon-carbon triple bonds or the 
corresponding 1,2,3-Triazole group (Figure 3.3). Primary substrate analogs were designed to mimic 
the di- and tri-methylammonium portion of the natural histone substrate. Secondary substrate 
analogs contain an α-keto group by a carboxylic acid or ester to mimic αKG and NOG. Several of 
the alkyne-containing compounds were tested for triazole formation in the enzyme-templated 
cycloaddition reaction, while some triazole-containing analogs were synthesized independently. We 
proposed that the analogs bearing the 1,2,3-Triazole group would be stronger inhibitors of KDM4 
than those bearing the alkyne functional group, because the alkyne could not coordinate to the 
KDM4 metal center. Moreover, we anticipate the triazole-containing compounds to be more 
selective for JmjC-HDMs than other αKG-dependent oxygenases because of the JmjC-HDMs low 
apparent affinities for O2.  
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Figure 3.3. Compounds tested as inhibitors of JmjC-HDMs. 
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3.2 Methods 
3.2.1 Synthesis of Primary Substrate Analogs 
Synthesis of 1a 
To a solution of 1.6 mL propargyl bromide (80% in toluene, 14.4 mmol) in 10 mL acetone 
was added 4.0 mL of 40% trimethylamine in H2O (29 mmol) dropwise while stirring at room 
temperature.  The solution was allowed to mix until no further color developed.  At this time, the 
organic layer was removed and the aqueous layer was washed two times with acetone. Then the 
aqueous layer was evaporated and 50 mL cold acetone was added to the residue. Upon addition of 
solvent, our product of interest precipitates out of solution and is collected by vacuum filtration.  
White crystalline, 1.95 g, 10.95 mmol, 76% yield.  1H NMR (D2O), δ: 4.78 (s, 1H), 4.24 (s, 2H), 3.21 
(s, 9H). 13C NMR (CD3OD), δ: 82.71 and 72.14 (C C), 57.13 (CH2), 53.48 (C3H9).  ESI-MS: M
+ of 
m/z 98.0969 (calculated), m/z 98.0965 (experimental). 
 
Synthesis of 1b 
To a solution of 1.0 mL 4-bromo-1-butyne (10.65 mmol) in 10 mL acetone was added 3.3 
mL of 40% trimethyl amine in H2O (24 mmol) dropwise while stirring.  No color developed upon 
addition of trimethyl amine.  The reaction was allowed to proceed at 30 °C for 3 h. The precipitate 
that had formed was collected by vacuum filtration and dried. White crystalline, 940 mg, 4.9 mmol, 
46% yield.  1H NMR ((CD3)2SO), δ: 3.51 (t, 2H), 3.13 (t, 1H), 3.09 (s, 9H), 2.77 (t, 2H). 
13C NMR 
(CD3OD), δ: 79.67 and 73.50 (C C), 65.71 (CH2-N), 54.12(t, C3H9), 14.80 (CH2-C C).  ESI-MS: 
M+ of m/z 112.1 (calculated), m/z 112.1 (experimental). 
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Synthesis of 1c 
To a solution of 1 mL of 6-chloro-1-hexyne (8.25 mmol) in 10 mL acetone was added 2.5 
mL 40% trimethylamine in H2O (18 mmol) dropwise while stirring. A yellow color developed upon 
addition.  The reaction was allowed to progress at 30 °C for 24 h, at which time more acetone was 
added to the reaction flask and the solvent was evaporated.  To the yellow residue remaining was 
added 50 mL cold acetone, resulting in the formation of crystals which were collected by vacuum 
filtration. White crystalline, 521 mg, 2.96 mmol, 36% yield.  1H NMR ((CD3)2SO), δ: 3.35 (m, CH2-
N), 3.07 (s, 9H), 2.88 (t, 1H), 2.24 (t, CH2-C C), 1.75 (m, CH2-CH2-N), 1.45 (CH2-CH2-C C). 
13C 
NMR (CD3OD), δ: 84.17 and 70.84 (C C), 67.32 (CH2-NMe3), 53.77 (t, C3H9), 26.40 (CH2-CH2-
NMe3), 23.15 (CH2-C C), 18.66 (CH2-CH2-C C).  ESI-MS: M
+ of m/z 140.1 (calculated), m/z 
140.1 (experimental). 
 
Synthesis of 3 
 
To a solution of 0.70 g 1-dimethylamino-2-propyne (8.42 mmol) in 15 mL dry THF at          
-78 °C was added n-BuLi (6.05 mL, 1.6 N, 9.68 mmol). The solution was kept under nitrogen and 
allowed to stir for 1 h, at which time 1.5 mL methyl chloroformate (19.41 mmol) was added 
dropwise. The reaction was allowed to warm to room temperature for 1 h.  The reaction was 
quenched upon addition of 10 mL H2O and the aqueous phase was extracted using ethyl ether (4 x 
25 mL).  The ethereal extracts were washed with 40 mL saturated NaCl, dried over MgSO4, and the 
crude residue was purified by flash chromatography (1:1 hexane : ethyl acetate). Amber oil, 294 mg, 
2.09 mmol, 25% yield.  1H NMR (CDCl3), δ: 2.35 (s, 6H), 3.42 (s, 2H), 3.78 (s, 3H). ESI-MS:       
[M + H]+ of m/z 142.1 (calculated), m/z 142.1 (experimental) 
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Synthesis of 5 
Compound 3 (60 mg, 0.425 mmol) was dissolved in 4.5 mL isopropanol at room 
temperature under nitrogen. 132 µL iodomethane (ρ 2.28 mg/mL, 2.12 mmol) was added, and the 
mixture was stirred for 5 h. The product was precipitated with 10 mL dry ethyl ether, collected by 
vacuum filtration, washed first with ether, and finally washed with pentane.  The result was a light 
tan powder, 82 mg, 0.29 mmol, 68% yield.  1H NMR (D2O), δ: 3.30 (s, 9H), 3.85 (s, 3H), 4.56 (s, 
2H). ESI-MS: [M + H]+ of m/z 156.1025 (calculated), m/z 156.1019 (experimental).   
 
General procedure for the Production of Triazoles Bearing Di- and Tri-Methylammonium 
Groups 
 
One equivalent of alkyne was dissolved in D2O or, if insoluble in water, deuterated DMSO, 
at a concentration of approximately 100 mg/mL. While stirring at room temperature, 5 equivalents 
of sodium azide were added, followed by one equivalent of ammonium chloride. The reaction 
proceeded under reflux at 100 °C and was monitored by 1H NMR, until complete. Once the reaction 
was complete, the solvent was distilled off and two consecutive cold EtOH washes were used to get 
rid of excess sodium azide.  Once the EtOH has evaporated, the product should be stored carefully 
owing to the hygroscopic nature of the triazole.   
 
Synthesis of 2a 
Compound 1a (500 mg, 2.81 mmol), 183 mg NH4Cl (2.81 mmol), and 913 mg NaN3 (14.05 
mmol) were dissolved in 5 mL D2O. Thirty two hours at 100 °C gave product at 92% completion; 
gold crystalline, 47% yield.  1H NMR (D2O), δ: 8.23 (s, 1H), 4.68 (s, 2H), 3.12 (s, 9H).  
13C NMR 
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(CD3OD), δ: 135.20 (CH=C), 132.91 (CH=C), 61.23 (CH2), 53.50 (C3H9). ESI-MS: M
+ of m/z 
141.1140 (calculated), m/z 141.1135 (experimental).     
 
Synthesis of 2b 
Compound 1b (300 mg, 1.56 mmol), 85 mg NH4Cl (1.56 mmol), and 510mg NaN3 (7.85 
mmol) were dissolved in 4 mL D2O. Ten days at 100 °C gave product at 95% completion; 118 mg 
yellow powder, 0.50 mmol, 32% yield. 1H NMR ((CD3)2SO), δ: 7.78 (s, 1H), 3.65 (t, 2H), 3.20 (t, 
2H), 3.14 (s, 9H). ESI-MS: M+ of m/z 155.1 (calculated), m/z 155.1 (experimental). 
 
Synthesis of 2c 
Compound 1c (150 mg, 0.86 mmol), 46 mg NH4Cl (0.86 mmol), and 280 mg NaN3 (4.3 
mmol) were dissolved in 5 mL D2O. Eleven days at 100 °C gave product at 86% completion; 26 mg 
yellow powder, 0.12 mmol, 14% yield. 1H NMR ((CD3)2SO), δ: 7.64 (s, 1H), 3.29 (d, 2H), 3.05 (s, 
9H), 2.59 (t, 2H), 1.74 (m, 2H), 1.60 (m, 2H). ESI-MS: M+ of m/z 183.2 (calculated), m/z 183.1 
(experimental). 
 
Synthesis of 4 
Compound 3 (320 mg, 2.26 mmol), 735 mg NaN3, (11.3 mmol), and 121.1 mg NH4Cl (2.26 
mmol) were dissolved in 4 mL (CD3)2SO. Five hours at 100 °C gave product at 100% completion. 
Purification was achieved via multiple washes with acetonitrile, as the desired product is insoluble. 
Medium brown powder, 368 mg, 2.0 mmol, 88% yield.  1H NMR (CD3OD), δ: 3.87 (s, 2H), 3.82 (s, 
3H), 2.27 (s, 6H). ESI-MS: [M+H]+ of m/z 185.1 (calculated), m/z 185.1 (experimental). 
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Synthesis of 6 
Compound 5 (30 mg, 0.106 mmol), 62.4 mg NaN3 (0.1 mmol), and 6 mg NH4Cl (0.11 
mmol) were dissolved in 3 mL D2O. Three hours at 100 °C gives product at 100% completion. Tan 
powder, 34.4 mg, 0.1 mmol, 100% yield.  1H NMR (D2O), δ: 4.77 (s, 2H), 3.90 (s, 3H), 3.10 (s, 9H). 
ESI-MS: M+ of m/z 199.1195 (calculated), m/z 199.1190 (experimental).   
 
3.2.2 Synthesis of Secondary Substrate Analogs 
Synthesis of 7a 
To 1.0 mL propargyl amine (14.5 mmol) at 0 °C and under nitrogen was added 2 mL 
distilled triethylamine (14.5 mmol) and a catalytic amount (~35 mg) of dimethylaminopyridine 
(DMAP) in 5 mL dichloromethane. The mixture was kept on ice and stirred 5 min.  Ethyl 
chlorooxoacetate (1.7 mL, ρ 1.227, 15.28 mmol) was added dropwise; upon completion of the 
addition, the reaction was allowed to progress on ice for 30 minutes, then at room temperature for 3 
h.  The addition of water marked the end of the reaction.  The desired product was extracted by 
using methylene chloride, followed by a chloroform extraction.  The chloroform-soluble fraction 
was collected, and the solvent was evaporated, resulting in a light yellow powder; 2.0 g, 13 mmol, 
87% yield.  1H NMR (CDCl3), δ: 7.56 (bs, 1H), 4.37 (q, 2H), 4.15 (dd, 2H), 2.30 (t, 1H), 1.39 (t, 3H).  
13C NMR (CDCl3), δ: 160.08 (COO), 156.38 (CON), 78.15 and 72.33 (C C), 63.32 (CH2CH3), 
29.28 (CH2-C C), 13.93 (CH3).  ESI-MS: [M+H]
+ of m/z 156.06 (calculated), m/z 156.22 
(experimental).  
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Synthesis of 8a 
 Compound 7a (154 mg, 1 mmol), 75 mg NaN3 (1.15 mmol), and 54 mg NH4Cl (1 mmol) 
were dissolved in 1 mL D2O to give a 1 M solution. The triazole product decomposes under 
vacuum, so the synthesis was done ≈ 1:1 alkyne:NaN3 to avoid the need to evaporate solvent. Reflux 
at 80 °C for 72 hours gave product at 100% completion; 100% yield. 1H NMR (D2O), δ: 4.03 (s, 
2H), 3.68 (q, 2H), 1.20 (t, 3H). ESI-MS: [M+H]+ of m/z 199.1 (calculated), m/z 199.0 
(experimental).  
 
Synthesis of 9a 
1-amino-4-chloro-2-butyne (1.015 g, 7.25 mmol) was dissolved in 10 mL dichloromethane at 
0 °C and under nitrogen. Distilled triethylamine (1 mL, 7.25 mmol) and a catalytic amount (~20 mg) 
of DMAP were added. The mixture was kept on ice and stirred 5 min.  Ethyl chlorooxoacetate (0.81 
mL, ρ 1.227, 7.28 mmol) was added dropwise. Upon completion of the addition, the reaction was 
allowed to progress on ice for 30 min, then at room temperature for 3 h.  The addition of water 
marked the end of the reaction.  The desired product was extracted by using methylene chloride, 
followed by a chloroform extraction.  The chloroform-soluble fraction was collected and the solvent 
was evaporated, resulting in a pale yellow, translucent oil; 1.4 g, 6.88 mmol, 95% yield. 1H NMR 
(CDCl3), δ: 7.51 (bs, 1H), 4.30 (q, 2H), 4.14 (m, 2H), 4.09 (t, 2H), 1.33 (t, 3H). 
13C NMR (CDCl3), 
δ: 159.95, 156.39, 80.90, 78.43, 63.27, 30.20, 29.59, 13.86. ESI-MS: [M + H]+ of m/z 204.0 
(calculated), m/z 203.9 (experimental).  
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Synthesis of 10a 
To 0.785 g 2-picolylamine (ρ 1.049 g/mL, 7.25 mmol) at 0 °C and under nitrogen was added 
1 mL distilled triethylamine (7.25 mmol) and a catalytic amount (~20 mg) of DMAP in 1 mL 
dichloromethane. The mixture was kept on ice and stirred 5 min.  Ethyl chlorooxoacetate (0.85 mL, 
ρ 1.227 g/mL, 7.6 mmol) in 3 mL dichloromethane was added dropwise; upon completion of the 
addition, the reaction was allowed to progress on ice for 30 min, then at room temperature for 3 h.  
The addition of water marked the end of the reaction.  The product of interest was extracted by 
using dichloromethane. Light tan powder, 1.33 g, 6.4 mmol, 88% yield. 1H NMR ((CD3)2SO), δ: 
9.43 (t, NH), 8.50 (d, 1H), 7.77 (t, 1H), 7.30 (t, 2H), 4.43 (d, 2H), 4.27 (q, 2H), 1.28 (t, 3H).  13C 
NMR (CDCl3), δ: 159.80 (COO), 155.77 (NH-CO), 149.10 (N=C(-R1 -R2)), 136.75 (N=CH-R1), 
122.40 121.93 121.65 (R1-CH=CH=CH-R2), 62.92 (CH2-CH3), 44.59 (CH2-NH), 13.84 (CH3). ESI-
MS: [M + H]+ m/z 209.1 (calculated), m/z 209.1 (experimental).  
 
General procedure for the synthesis of 7b, 9b, and 10b 
 1 equivalent (~ 0.5 – 1.5 mmol) of the ester-containing precursor (7a, 9a, 10a) was dissolved 
in 5-10 mL 1:1 MeOH:THF at room temperature.  While stirring, 1.1 equivalent NaOH in H2O was 
added dropwise, resulting in precipitation of product as a salt. Following removal of solvent under 
reduced pressure, the salt product was dissolved in a few mLs of H2O, and HCl was added to 
neutralize or acidify the solution. Finally, the solvent was removed under reduced pressure, resulting 
in solid product.  
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Synthesis of 7b 
 Compound 7a (66 mg, 0.43 mmol) was dissolved in 6 mL 1:1 MeOH:THF at room 
temperature. NaOH solution (0.45 mL of 1 M) was added dropwise. The solution was left to stir for 
one day. Off white crystalline, 65 mg, 0.43 mmol, 100 % yield. 1H-NMR (CDCl3) of acidified 
product, δ: 7.22 (bs, 1H), 4.16 (dd, 2H), 2.34 (t, 1H). ESI-MS: [M+H]+ of m/z 128.0432 
(calculated), m/z 128.0342 (experimental).  
 
Synthesis of 9b 
 Compound 9a (82 mg, 0.4 mmol) was dissolved in 6 mL 1:1 MeOH:THF at room 
temperature. NaOH solution (0.43 mL of 1 M) was added dropwise. The solution was left to stir for 
one day. White powder, 80 mg, 0.4 mmol, 100% yield. 1H-NMR ((CD3)2SO) of acidified product, δ: 
8.78 (t, NH), 4.43 (s, 2H), 4.2 (bs, 1H), 3.91 (d, 2H). 13C-NMR ((CD3)2SO) of acidified product, δ: 
164.6, 162.7, 83.9, 76.7, 31.1, 28.3.  
 
Synthesis of 10b 
  Compound 10a (300 mg, 1.44 mmol) was dissolved in 8 mL 1:1 MeOH:THF at room 
temperature. NaOH solution (1.6 mL of 1 M) was added dropwise. The solution was left to stir for 
one day. White powder, 290 mg, 1.44 mmol, 100% yield. 1H-NMR ((CD3)2SO), δ: 9.46 (t, NH), 8.63 
(d, 1H), 8.06 (t, 1H), 7.54 (m, 2H), 4.55 (s, 2H). ESI-MS: [M+H]+ of m/z  181.1 (calculated), m/z 
181.0 (experimental).  
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3.2.3  MALDI-TOF Mass Spectrometry Inhibition Assay 
Primary Substrate Analog Screening Assay 
 Purified KDM4E (8 µM) was incubated for 10 minutes at room temperature with 40 µM 
FeII(NH4)2SO4·6H2O, 300 µM αKG, 500 µM sodium L-ascorbate, and 1 mM primary substrate 
analog. The demethylation reaction was started by the addition of H3(7-14)K9me3 (30 µM or 250 µM), 
and allowed to progress at 37 °C (2 or 10 min). At that time, the reaction was stopped by the 
addition of 2x MeOH and 0.1% TFA. The precipitated protein was removed via centrifugation, and 
a portion of the supernatant was mixed with 10 mg/mL α-cyano-4-hydroxycinnamic acid in 50% 
acetonitrile/0.1% TFA. All samples were done in duplicate. To avoid bias in the collection of 
MALDI spectra, all samples were analyzed using accumulated spectra of at least 1000 shots.  
Percent demethylation values were determined using the relative intensities of  the mono-,  
di-, and tri-methylated H3(7-14)K9 peaks in the following equation (3-1): 
                 
                  
                        
  (3-1) 
 Percent demethylation values were converted to “Demethylation factors” by taking the 
control percent demethylation to be 100% or 1.00.  
Secondary Substrate Analog Screening Assay 
 Purified KDM4E (8 µM) was incubated for 10 min at room temperature with 40 µM 
FeII(NH4)2SO4·6H2O, 500 µM sodium L-ascorbate, and 1 mM secondary substrate analog. The 
demethylation reaction was started by the addition of αKG (75 µM or 500 µM) and H3(7-14)K9me3 
(175 µM), and allowed to progress for 10 min at 37 °C. At that time, the reaction was stopped by the 
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addition of 2x MeOH and 0.1% TFA. The precipitated protein was removed via centrifugation and 
a portion of the supernatant was mixed with 10 mg/mL α-cyano-4-hydroxycinnamic acid in 50% 
acetonitrile/0.1% TFA. All samples were done in duplicate. To avoid bias in the collection of 
MALDI spectra, all samples were analyzed by using accumulated spectra of at least 1000 shots. 
Demethylation factors were calculated in the same way as in the primary substrate analog screening 
assay. 
 
3.2.4 Enzyme-Templated Cycloaddition Reaction 
 In a typical assay, purified HDM (150 - 250 µM, 1 equivalent) is reconstituted with 1 
equivalent metal salt (Fe2+ or Ni2+), then incubated with three equivalents alkyne and an excess of 
NaN3 (> 50 equivalents) in Tris or HEPES buffer (pH 7.5) at 4 °C for 24 hours. For primary 
substrate analogs, an appropriate amount of αKG was added to the solution as well. After 24 hours, 
a portion of the reaction solution is diluted with MeOH, the protein precipitate removed via 
centrifugation, and the supernatant is analyzed via ESI-MS (Thermo LCQ Deca).  
 
3.3 Results and Discussion 
 Early crystallography studies of KDM4A revealed the basis for its primary and secondary 
substrate specificities.5  As shown in Figure 3.4, the interaction of N-oxalylglycine (NOG; an analog 
of the secondary substrate α-ketoglutarate) with KDM4A is due to the oxalyl portion chelating the 
metal center, while the other carboxylic group forms a hydrogen bond with Tyr 132. KDM4 
recognition of the histone lysine substrate involves multiple interactions of the enzyme with both 
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histone main-chain and histone methyl lysine groups. Also shown in Figure 3.4, the histone H3 
trimethylated lysine’s methyl groups make multiple contacts with KDM4A residue oxygen atoms: 
Gly 170, Glu 190, Ser 288, and Tyr 177 (distance of 3.5 Å, omitted for clarity). All of these 
R3N+─C─H ···· O═C contacts are at distances less than 3.7 Å, which makes them consistent with 
CH ···· O hydrogen bonding.29 It is, therefore, supposed that KDM4 recognition of the histone 
substrate is due in part to these hydrogen bonds.  
 
Figure 3.4. Recognition of H3K9me3 and NOG in the KDM4A active site (PDB 2OQ6; distances in 
Å).5 
 
 At the start of this work, it was unknown whether inhibition of KDM4 isoforms could be 
achieved through the use of simple substrate analogs bearing dimethylamino or trimethylammonium 
groups to mimic the natural lysine substrate. We, therefore, synthesized a small library of primary 
substrate analogs that include either a carbon-carbon triple bond or the corresponding 1,2,3-triazole 
group (Figure 3.5) and screened the compounds for inhibition against KDM4E by using a 
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discontinuous MALDI-TOF MS assay. The alkynes were tested in KDM4-templated cycloaddition 
reactions (vide infra), and the corresponding triazole-containing compounds were synthesized 
independently to test whether they would be stronger KDM4 inhibitors than the alkyne-containing 
compounds.  KDM4E was the enzyme chosen for the inhibition screen, as it displays the greatest in 
vitro activity of our three isoforms (which include KDM4A and KDM4C); however, it is a 
pseudogene-encoded HDM and is dissimilar to KDM4A and KDM4C in that it recognizes only 
H3K9me3 and not H3K36me3.  
In the inhibition screen, 8 µM KDM4E was incubated with 1 mM primary substrate analog 
and all other reaction components except the histone peptide substrate H3(7-14)K9me3. To start the 
reaction, histone peptide was added at a concentration of 50 µM (≈ Km) or 250 µM. Screening the 
inhibitors at two concentrations of peptide substrate allows us to test whether any of the analogs 
potentially compete with the histone peptide substrate. If inhibition of KDM4E by an analog 
increased at the low peptide concentration, we would have a template around which to design a 
library of potential JmjC-HDM specific inhibitors.   
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  From Figure 3.5, we find that the most potent inhibition of KDM4E comes from analog 5 
and the corresponding triazole 6. As the dimethylamino analogs 3 and 4 inhibit KDM4E to a lesser 
degree, 5 and 6 may illustrate the benefit of including a trimethylammonium fragment in the design 
of simple JmjC-HDM inhibitors. Notably, neither 5 nor 6 show substantial increased inhibition at 
the lower peptide concentration, leading us to assume that these analogs bind the enzyme in a 
pocket other than the histone peptide binding cavity.  
Our findings confirm that enzymatic recognition of the substrate involves more than just the 
presence of a trimethylammonium group, as demonstrated by the limited inhibition of KDM4E by 
analogs 1a, 1b, and 1c. We see somewhat more inhibition when testing the triazole versions of these 
analogs, as shown by the inhibitory effects of 2a and 2c at lower histone peptide concentrations. In 
comparing 2a and 2c, assuming the triazole portion interacts with the metal center, the longer alkyl 
chain of 2c may position the trimethylammonium in a more favorable position to form CH ···· O 
hydrogen bonds, leading to slightly greater inhibition of KDM4E.  
In the primary substrate analog screen, we find that the triazole compounds 2a, 2b, 2c, and 6 
inhibit KDM4E slightly more than the equivalent alkyne-containing compounds 1a, 1b, 1c, and 5. 
This trend is more apparent at the low histone peptide concentration. Interestingly, the triazole-
containing 4 is a weaker KDM4E inhibitor than 3 at both histone peptide concentrations. As the 
only difference between 4 and 6 is an additional methyl group in 6 (and thus a positive charge on 
nitrogen), we can infer the importance of the trimethylammonium group in KDM4E recognition of 
this scaffold. Testing compound 6 in varying O2 concentration environments with our developed O2 
consumption assay (Section 2.2.3) would allow us to assess whether this analog competes with the 
cosubstrate for binding to the active site metal center. Furthermore, modification of 5 and 6 could 
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lead to the development of potent, specific inhibitors of JmjC-HDMs, as we would not anticipate 
these templates to be promiscuous inhibitors of αKG- dependent oxygenases. 
Since it is clear that recognition of the natural trimethyllysine substrate involves multiple 
main chain interactions of the peptide with the HDM, we next directed our attention to developing 
analogs of the secondary substrate αKG, using the same alkyne and triazole strategy as in the 
primary substrate analog screen. As shown in Figure 3.6, the analogs mimic the αKG amide analog 
NOG in that they each contain the amide oxalyl functional group.  
The KDM4E inhibition screen was done in a similar manner to the primary substrate analog 
screening, with a pre-incubation of 8 µM HDM and 1 mM analog, but the reaction was started by 
the addition of 175 µM histone peptide and one of two αKG concentrations: 75 µM (≈ 3x Km) or      
500 µM, to test whether the analogs are αKG competitors. Unfortunately, the nature of the 
discontinuous MS assay does not allow for “low” (Km) concentrations of αKG to be used, since we 
saw no substantial demethylation of the peptide substrate at αKG concentrations less than 75 µM. 
For example, under the secondary substrate analog screening assay conditions, with no inhibitor 
present, use of 20 µM αKG (≈ Km) resulted in under 10% demethylated product (i.e. the relative 
intensities of the H3K9me3 and H3K9me2 peaks are 100% and 10%, respectively). Such low 
percentages of demethylated product make quantification of enzyme inhibition impossible. Use of 
75 µM αKG results in approximately 40% demethylated product, a high enough percentage to allow 
for proper inhibition analysis.  
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Azide (11), 1,2,3-triazole (12), and NOG (13) were used as controls in the KDM4E inhibition 
screen. Compounds 11 and 12 should be competitors of O2, and, thus, we would expect no 
difference in their inhibition at varying concentrations of αKG. As shown in Figure 3.6, even at the 
relatively high concentration of 1 mM, 11 and 12 have limited inhibitory power. Under the inhibitor 
screening conditions, the known JmjC-HDM inhibitor30 NOG does not appear to compete with 
αKG, its isosteric analog, as we do not see a dramatic difference between the level of inhibition at 
the different concentrations of αKG. Finally, ester analogs 7a, 9a, and 10a are synthetic precursors 
to the carboxylic acid analogs, and were used as controls in the inhibition screen. Predictably, we 
find no enzyme inhibition with the ester-containing analogs.  
Preliminary results with 7b suggested that the compound had limited inhibitory power, 
leading us to design 9b and 10b, as it was unclear why the oxalyl portion of 7b was insufficient in 
limiting αKG binding in the KDM4E active site. The pyridine moiety in 10b is a known metal 
chelator, and we find that this analog inhibits KDM4E at about the same level as 7b, at least at the 
higher αKG concentration where quantification of demethylation is more reliable. This result is 
surprising, if we assume the oxalyl portion of each to interact with the metal center, as the pyridine 
in 10b could offer more favorable interactions with KDM4E residues than the C≡C in 7b. With 9b, 
we were interested to see how a chlorinated compound would affect enzyme activity, as early studies 
with the compound JIB-04 (Figure 3.1; see Chapter 5 for further discussion) indicate that the 
chlorine interacts with the JmjC-HDM active site metal. We lose inhibitory power when modifying 
7b to 9b. If the oxalyl portion of 7b interacts with Fe in a manner similar to αKG, perhaps the 
chlorine of 9b is too large to fit in the active site. As 7b, 9b, and 10b are all weak inhibitors of 
KDM4E, our results suggest that the hydrogen bond formed between NOG and Tyr132 (Figure 
3.4) is perhaps the key stabilizing interaction necessary for proper JmjC-HDM inhibition.   
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 The only secondary substrate analog that shows inhibitory strength comparable to 13 is 8a, 
the ester- and 1,2,3-triazole-containing version of 7a. This product decomposes under reduced 
pressure and, thus, was synthesized from 7a in aqueous solution. For this reason, we were unable to 
generate the carboxylic acid form of 8a. Although we know from the NOG control that large 
differences in inhibition are unlikely under the screening conditions for αKG competitors, KDM4E 
inhibition by 8a is identical at both concentrations of αKG, which could be due to it being an ester 
instead of an acid. Thus, 8a is most likely not competitive with αKG, but could be competitive with 
O2 owing to the inclusion of 1,2,3-triazole. As was discussed for the primary analog 6, testing 
KDM4E inhibition by 8a at varying concentrations of O2 would allow us to judge whether this 
triazole is competitive with O2. 
 Finally, several analogs were tested in the HDM-templated cycloaddition reaction: 1a, 1b, 1c, 
3, 5, and 7b. No evidence of triazole formation was found in the enzyme-templated reaction for 1a, 
1b, 1c, or 7b. From the KDM4E inhibition screen, we know that these compounds have limited 
inhibitory power and, therefore, low binding affinities. 3 and 5 were of interest as these compounds 
were found to be relatively good inhibitors of KDM4E. However, we found that 3 and 5 undergo 
cycloaddition with N3
- in solution, even at 0 °C, as evidenced by ESI-MS and 1H-NMR. The ESI-MS 
time study for compound 5 is given as a representative in Figure 3.7. Thus, these two compounds 
have C≡C bonds that are too electron deficient to be used in the enzyme-templated reaction. As 5 
and the corresponding triazole 6 were found to be the strongest inhibitors of KDM4E tested, these 
compounds could act as templates for future development of JmjC-HDM inhibitors.  
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Figure 3.7. ESI-MS of 5 with excess N3
- in water at (top) 0 minutes and (bottom) 30 minutes. The peak 
at m/z of 156 corresponds to the alkyne starting material 5, m/z of 199 corresponds to the triazole 
product 6.  
 
3.4 Conclusions 
 In conclusion, we have synthesized a small library of molecules designed to mimic JmjC-
HDM primary and secondary substrates. These small molecules include either a carbon-carbon triple 
bond or 1,2,3-triazole group and were tested as inhibitors of the H3K9me3/2 demethylase KDM4E 
using a discontinuous MALDI-TOF MS assay. Overall, we find that triazole-containing analogs were 
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more potent inhibitors than the alkyne-containing analogs, with the exception of 3 and 4. The most 
promising primary substrate analogs 5 and the corresponding triazole 6 present a new scaffold for 
KDM4 inhibition. While none of the secondary substrate analogs were found to strongly inhibit 
KDM4E, the triazole 8a may be competitive with O2 and appears to inhibit KDM4E nearly as well 
as NOG. Several of the alkyne-containing analogs were tested in KDM4-templated cycloaddition 
reactions, and no enzyme-driven triazole formation was found. Future studies will focus on the 
modification of compounds 5 and 6 to increase their inhibitory power. Moreover, these compounds 
can be screened against other αKG-dependent oxygenases, as we anticipate them to offer         
JmjC-HDM-specific inhibition. 
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Chapter 4: Inhibition of JmjC-Histone Demethylases 
with a Modified Histone H3 Peptide 
 
4.1 Introduction 
Several reports have elucidated reasons behind the KDM4 subfamily substrate specificities.1-5 
Although KDM4D is active toward H3K9me3 only, other members of the subfamily (KDM4A, B, 
C) show activity towards both H3K9me3 and H3K36me3, despite low sequence homology of the 
two histone sites.6 The KDM4 subfamily members have very similar active-site topologies, and the 
residues lining the methylammonium-binding pocket are highly conserved.5 Overall, KDM4 
subfamily substrate selectivities come from the amino acid residues surrounding the di- or tri-
methylated lysine. Recognition of the histone substrate is due primarily to contacts with main-chain 
atoms of the substrate, rather than the side-chain atoms. One notable exception is the side chain of 
arginine at the -1 position in H3K9, which hydrogen bonds with the carboxylate of Glu169 in 
KDM4A.  Other peptide residues important for recognition are the alanine at -2 and serine at +1.3 
For KDM4A, the Gly-Gly motif (at +3 and +4 in H3K9) is reported to be essential for enzymatic 
activity.4  
With this knowledge, several recently designed KDM4-specific inhibitors include a short 
peptide fragment to enhance HDM recognition of the substrate analog.7, 8 KDM4C is capable of 
recognizing the truncated peptide fragment H3(7-10)K9me3, while the shortest peptide KDM4A 
recognizes is H3(7-14)K9me3. Interestingly, deletion of even one methylene group from the K9men   
(n = 2, 3) side chain results in no demethylation by KDM4A or KDM4C. One report details an 
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effort to make an inhibitor with isoform specificity: a five amino acid-long peptide H37-11K9 was 
synthesized with an iron chelator (a uracil) at the Nε position of K9 (Figure 4.1). The 5-mer was 
chosen because it would be selective for KDM4C over KDM4A; using the modified peptide, the 
authors report a Ki of 27μM for KDM4C and a Ki of 118μM for KDM4A, while finding no 
inhibition of the related H3K9me2/1 demethylase PHF8.
7   
 
Figure 4.1. A substrate-based inhibitor, selective for KDM4C over PHF8.7 
 
A more recent report used the 8-mer H3(7-14)K9me3 with an iron chelator (N-oxalyl-D-
cysteine) connected to the peptide at the threonine (+2) position. This modified peptide inhibits 
KDM4A and KDM4E selectively over αKG oxygenases FIH, PHD2, and JMJD1E.8 We see from 
these reports that the development of specific inhibitors of the KDM4 subfamily members may 
require the inclusion of a peptide fragment.  
In this study, we developed a modified histone H3 peptide with the intention of selectively 
inhibiting KDM4C over KDM4A. The 5-mer H3(7-11)K9(N
ε-bis(propargyl)) incorporates two 
propargyl groups conjugated to lysine’s Nε in place of the natural trimethyl ammonium group. 
Moreover, a methylated 5-mer H3(7-11)K9
+(Nε-methyl (bis-propargyl)) was produced to test whether a 
charged K9 would enhance recognition of the peptide by the KDM4 subfamily, thus enhancing 
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inhibition of this group of enzymes. Surprisingly, we found that KDM4A can indeed recognize the 
methylated 5-mer, challenging earlier studies of the enzyme with the more natural H3(7-11)K9me3 
peptide.7  
An ongoing interest in our study of the KDM4 subfamily revolves around whether these 
enzymes are suited to act as “vessels” in enzyme-templated Huisgen 1, 3-dipolar cycloaddition 
reactions between enzyme-azide adducts and small molecules bearing carbon-carbon triple bonds. 
As earlier studies of KDM4-templated cycloaddition of simple alkynes bearing trimethylammonium 
groups with the enzyme-azide adduct failed to show triazole formation (Chapter 3), the 5-mers in 
this study were designed to project the propargyl groups toward the metal center in the KDM4C 
active site (Scheme 4.1).  
 
Scheme 4.1. Huisgen 1, 3-dipolar cycloaddition of ARK+(Nε- methyl bis(propargyl))ST with a 
KDM4-M2+-azide adduct. 
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4.2 Methods 
4.2.1 Synthesis of a Modified Histone H3 Peptide 
Synthesis of Boc-Lys(Nε -bis-(propargyl))-OMe 9 
Boc-Lys-OMeHCl (4 g, 13.48 mmol) was dried under vacuum at 35 °C for two hours, then 
62.5 mL tetrahydrofuran (THF) was added under nitrogen and the temperature was raised to 50 °C. 
Next, 4.5 mL pyridine (54 mmol) and 5.8 mL propargyl bromide (80% in toluene, 54 mmol) were 
added slowly. Following the addition of propargyl bromide, the solution turned from clear and 
colorless to cloudy and orange. The reaction was followed by TLC; after 4 days at 50 °C, the 
reaction solution was vacuum filtered, and the filtrate was concentrated. Pure product was extracted 
from the dark brown, oily crude through warm 1:2 ethyl acetate:hexane washes; yellow oil, 1.5 g, 
4.46 mmol, 33% yield. 1H NMR (CDCl3), δ: 5.0 (d, 1H), 4.30 (m, 1H), 3.74 (s, 3H), 3.41 (d, 4H), 
2.51 (t, 2H), 2.22 (t, 1H), 1.80 (m, 2H), 1.65 (m, 2H), 1.50 (m, 1H), 1.44 (s, 9H), 1.25 (s, 2H). 13C 
NMR (CDCl3), δ: 173.24, 155.29, 79.54, 78.61, 73.04, 53.49, 53.23, 52.27, 41.91, 32.22, 28.21, 26.73, 
22.96. See Appendix B for NMR spectra. ESI-MS [M + H]+ m/z 337.2 (calculated), m/z 337.2 
(experimental).  
Synthesis of ARK(Nε- bis(propargyl))ST 
 Boc-Lys(Nε -bis-(propargyl))-OMe (1 g) was sent to AnaSpec Inc. for synthesis of the 
desired peptide; 25 mg of mostly pure product was generated with impurities that include 
incomplete peptides RK(Nε -bis(propargyl))ST and K(Nε –bis(propargyl))ST. ESI-MS and MALDI-
TOF MS: [M + H]+ m/z 638.3 (calculated), m/z 638.3 (experimental). While we find no evidence of 
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the mono-propargyl species in the ESI-MS, we do find an [M + H - 38]+ peak in the MALDI-TOF 
mass spectrum (Appendix B).  
Synthesis of ARK+(Nε- methyl bis(propargyl))ST 
 ARK(Nε-bis(propargyl))ST (3.9 mg, 6.1 mol) was dissolved in 20 µL DMSO. Methyl iodide 
(10 µL, ρ 2.28 g/mL, 161 µmol) was dissolved in 10 µL DMSO, and the methyl iodide solution was 
added directly to the peptide solution at room temperature. The reaction solution was mixed for 2 h 
at room temperature, and at this time ESI-MS showed no remaining starting material. To quench 
excess methyl iodide, water was added to create a 30 mM stock solution. ESI-MS and MALDI-
TOF MS: M+ of m/z 652.4 (calculated), m/z 652.4 (experimental). While few find no evidence of 
the mono-propargyl species in the ESI-MS, we did find an [M-38]+ peak in the MALDI-TOF mass 
spectrum (Appendix B).  ESI-CID-MS/MS: Following ion selection at 326.8 (M2+), fragments at 
425.3 (K+meST)
1+ and 232.7 (ARK+me)
2+ confirm that lysine is the methylated residue of the 5-mer. 
Absent from the spectrum is any peak that could correspond to arginine being the methylated 
residue. See Appendix B for relevant spectra.  
 
4.2.2 MALDI-TOF Mass Spectrometry Assays 
KDM4A and KDM4C Inhibition by ARK(Nε bis(propargyl))ST and            
ARK+(Nε methyl bis(propargyl))ST 
Purified HDM (6 µM) was incubated for 10 minutes at room temperature with 30 µM 
FeII(NH4)2SO4·6H2O, 300 µM α-ketoglutarate (pH 7.5), 500 µM sodium L-ascorbate, 50 mM 
HEPES pH 7.5, and varying ARK(Nε -bis(propargyl))ST (0 – 1000 µM) or                           
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ARK+(Nε -methyl bis(propargyl))ST (0 – 1000 µM). The reaction is started by the addition of 60 µM 
H3(7-14)K9me3 and allowed to progress for 20 min at 37 °C. To stop the reaction, the solution was 
diluted two times with methanol and centrifuged, and the supernatant was collected. Supernatant 
was mixed 1:1 with 10 mg/mL α-cyano-4-hydroxycinnamic acid in 50% ACN/0.1% TFA, and the 
mixture was spotted directly onto the MALDI plate. For analysis, an ABI DE-STR MALDI TOF 
instrument was used.  
As a control for the ARK+(Nε methyl bis(propargyl))ST inhibition study, the inhibition of 
KDM4A and KDM4C by a solution of CH3I in H2O/DMSO was tested. The solution was made by 
dissolving 10 µL methyl iodide in 30 µL DMSO, then by diluting this five times with H2O.  Using 
this as the “30 mM” stock solution, enzyme inhibition was tested as above, in concentrations varying 
from “0 – 1000 µM” CH3I solution.   
 
Demethylation of ARK+(Nε -methyl bis(propargyl))ST by KDM4A, KDM4C, and KDM4E 
Purified HDM (8 µM) was incubated with 50 mM HEPES pH 7.5, 40 µM 
FeII(NH4)2SO4·6H2O, 300 µM αKG, 500 µM sodium L-ascorbate, and 400 µM                    
ARK+(Nε methyl bis(propargyl))ST at room temperature for varying amounts of time (0, 5, 20, and 
60 min). At each time point, the solution was diluted two times with methanol and centrifuged, and 
the supernatant was collected. Supernatant was mixed 1:1 with 10 mg/mL α-cyano-4-
hydroxycinnamic acid in 50% ACN/0.1% TFA, and the mixture was spotted directly onto the 
MALDI plate.  
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In situ click chemistry studies with ARK(Nε -bis(propargyl))ST and ARK+(Nε -methyl 
bis(propargyl))ST 
Purified HDM (250 µM) was incubated with 250 µM NiCl2·6H2O or Fe
II(NH4)2SO4·6H2O, 
followed by the addition of 2 mM αKG pH 7.5, 1 mM NaCl, 750 µM ARK(Nε bis(propargyl))ST or 
ARK+(Nε methyl bis(propargyl))ST, 200 mM NaN3, and HEPES pH 7.5. The incubation was done 
at varying temperatures (4, 20, and 37 °C) and for varying amounts of time (4 – 24 h). “Metal-only” 
controls (i.e. 250 µM NiCl2·6H2O or Fe
II(NH4)2SO4·6H2O without HDM) were done for each 
experimental setup. For analysis, a portion of each sample was diluted two times with 50 mM 
EDTA (pH 8.0), then diluted ten times with MeOH:H2O.  Each solution is centrifuged, and the 
supernatant was collected and desalted using ZipTip (C18) or ZipTip (SCX) and spotted onto the 
MALDI plate, either directly or after eluting with matrix solution. Matrix solution containing 10 µM 
standard  (H3(7-14)K9me3) was layered on top of each spot for calibration purposes.  
 
4.2.3 Docking studies of ARK(Nε- bis(propargyl))S  with KDM4A 
 Low energy conformers of ARK(Nε bis(propargyl))S were generated using OMEGA 
following minimization by SZYBKI (both OpenEye). The conformers were modeled into the 
KDM4A active site (PDB 2Q8C) with OpenEye’s HYBRID ligand-guided docking program using 
the Poisson-Boltzmann solvation method at 310 K, taking into account cavity solvation energies. All 
renderings were generated using PyMol.  
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4.3 Results and Discussion 
 As members of the KDM4 subfamily of JmjC-HDMs are candidate oncogenes, inhibition of 
these enzymes is an active area of study. However, selective inhibition is of the utmost importance, 
as other JmjC-HDM subfamilies may have members that act as tumor suppressors. Achieving 
subfamily or isoform selectivity within the JmjC-HDMs is proving difficult for several reasons. First, 
many JmjC-HDMs have similar active-site structures owing to high sequence homologies. Secondly, 
inhibitors designed to bind the ferrous iron in place of αKG in the active site can be promiscuous in 
nature, and may interfere with other histone-modifying metalloenzymes.10, 11 Lastly, primary 
substrate recognition involves both catalytic (JmjC, JmjN) and non-catalytic (PHD, Tudor-Tudor) 
domains, complicating substrate-based inhibitor design efforts.1, 4, 5, 12-14  
Using a peptidomimetic approach, we designed a modified H3K9 peptide in an effort to 
selectively inhibit KDM4C over the closely related enzyme KDM4A, as the two are thought to 
contribute to different cancers through varying mechanisms.15-20 In this study, the inhibitor is a       
5-mer H3(7-11)K9 (ARKST) containing a lysine residue with two propargyl groups attached to the 
epsilon nitrogen.  Shown in Figure 4.2 is the methylated version of the peptide,                  
ARK+(Nε- methyl bis(propargyl))ST, designed to test whether inhibition of KDM4C would be 
increased with a charged lysine as in the natural trimethylammonium substrate.  
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Figure 4.2. The novel histone H3 peptide, ARK+(Nε- methyl bis(propargyl))ST, designed to 
selectively inhibit KDM4C over KDM4A.  
 
  
Both peptides were devised to have the Nε propargyl groups project toward the Fe(II) metal 
center in the KDM4C active site. Such positioning of the propargyl groups would be desirable for 
two reasons. First, we could test whether either of the enzymes could hydroxylate this non-natural 
alkyl substrate, as another study had shown KDM4E to have activity toward H3K9(Nε-ethyl) 
substrates.21 Second, positioning the propargyl groups to project toward the metal center could serve 
to facilitate triazole formation between the alkyne(s) and an HDM-metal-azide complex. This in situ 
click chemistry has been a topic of interest in our studies and has been explored for various alkyne-
containing substrates, with no concrete evidence of enzyme-driven triazole formation. Thus, a 
peptide that should be recognized by KDM4C containing propargyl groups aimed at the metal 
center provides a good opportunity to test whether KDM4C is capable of acting as the reaction 
“vessel” for triazole formation.   
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Since no crystal structure of KDM4C in ternary complex with an H3K9 peptide has been 
solved, docking studies of our novel peptide ARK(Nε-bis(propargyl))ST were done with the catalytic 
core of KDM4A (Figure 4.3). We find that the most favorable conformation has the termini of the 
two propargyl groups at distances of 4.0 and 5.2 Å from the metal center. An approximate distance 
of 5 Å should provide sufficient room for reaction between an FeIV-oxo species and alkyl substrate.22  
   
Figure 4.3. (left) H3(7-14)K9me3 crystallized in the KDM4A active site; (right) H3(7-14)K9(bis(propargyl)) 
docked into the KDM4A active site. 
 
We first tested for selective inhibition of KDM4C over KDM4A with the non-methylated 
peptide ARK(Nε- bis(propargyl))ST using a discontinuous MALDI-TOF MS assay. Briefly, all 
reaction components aside from the natural primary substrate (ARKme3STGGK) were incubated 
with the holoenzyme for several minutes, a method common for substrate-based inhibitors.8 After 
addition of the primary substrate, the demethylation reaction was allowed to progress, and then 
stopped by precipitation of the protein. Analysis of samples ranging in concentration of      
ARK(Nε- bis(propargyl))ST from 0 – 1000 µM reveal that this peptide does indeed selectively inhibit 
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KDM4C over KDM4A (Figure 4.4). Although we find no inhibition of KDM4A, the inhibition of 
KDM4C is quite mild, with an IC50 greater than 1 mM.  




 
Figure 4.4. Selective inhibition of KDM4C over KDM4A using ARK(Nε-bis(propargyl))ST. 
 
Next, ARK(Nε- bis(propargyl))ST was methylated to ARK+(Nε- methyl bis(propargyl))ST 
using  methyl iodide. Confirmation that lysine was the methylated residue came from ESI-CID-
MS/MS analysis (Appendix B). As the natural KDM4C substrate, H3K9me3/2, features a positively 
charged lysine, we posited that the methylated peptide would lead to increased inhibition of 
KDM4C. Using the same MALDI-TOF MS assay, we obtain surprising results. Not only do we see 
increased inhibition of KDM4C with the methylated peptide (logIC50 = -3.355 ± 0.120; IC50 ≈ 440 
µM), we see a similar level of inhibition of KDM4A (logIC50 = -3.269 ± 0.048; IC50 ≈ 540 µM) 
(Figure 4.5 and Table 4.1). This inhibition of KDM4A was unexpected as an earlier study had found 
KDM4A to be incapable of recognizing a peptide shorter than H3(7-14)K9.
7  
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
   

    
Figure 4.5. Inhibition of KDM4A (top) and KDM4C (bottom) by ARK+(Nε- methyl bis(propargyl))ST. 
  
Conversion of the IC50 values obtained above to apparent Ki binding affinities can be done 
using the Cheng-Prusoff equation (4-1).23 Using the H3(7-14)K9me3 Km values obtained in Chapter 2 
of this work, we find that the Ki
app for KDM4A is approximately 184 µM; for KDM4C, Ki
app is      
153 µM.  While neither of these binding affinities is remarkably high, it is worth noting that these 
small molecules are inhibiting KDM4A and KDM4C without chelating the metal center in the active 


IC50 = 440 M

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site. Thus, to our knowledge, this is the first peptide-based inhibitor of KDM4 isoforms that does 
not include an αKG analog to enhance inhibitory effectiveness.7, 8  
   
    
  
   
  
         (4-1) 
Table 4.1. Inhibition data for KDM4A and KDM4C with modified H3K9 peptides.a  
 ARK(Nε- bis(propargyl)ST ARK+(Nε- methyl bis(propargyl)ST 
 IC50 Ki
app IC50 Ki
app 
KDM4A N.D. N.D. 540 µM 184 µM 
KDM4C > 1 mM > 340 µM 440 µM 153 µM 
a See section 4.2.2 for experimental conditions. 
Previous studies found KDM4A to demethylate H3K9me3 three-fold more efficiently than 
H3K9me2, with KDM4C behaving similarly.
1, 5 In this study, we found a near 3-fold increase in 
KDM4C inhibition when modifying our H3K9 peptide from a Lys- Nε tertiary amine to a 
quaternary amine. While we anticipated an increase in inhibition of KDM4C when moving from 
ARK(Nε- bis(propargyl))ST to ARK+(Nε- methyl bis(propargyl))ST, it was surprising to see such 
inhibition of KDM4A when using the methylated peptide. As KDM4A does not appear to have 
demethylase or hydroxylase activity towards the modified peptide (vide infra), the positive charge on 
K9 may provide enough favorable electrostatic interaction in or near the KDM4A active site to 
weaken the enzyme’s ability to bind the more natural ARKme3STGGK substrate.  
To ensure that ARK+(Nε- methyl bis(propargyl))ST is the species responsible for the 
observed inhibition, a solution of methyl iodide in H2O/DMSO was tested against KDM4A and 
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KDM4C, as the ARK+(Nε- methyl bis(propargyl))ST reaction solution contained excess methyl 
iodide quenched with H2O. As seen in Figure 4.6, there is minimal inhibition of KDM4C using the 
methyl iodide solution, and virtually no inhibition observed for KDM4A.  
 
 
Figure 4.6. Minimal inhibition of KDM4A (left) and KDM4C (right) using a methyl iodide solution. 
   
 We next tested to find if any of our three JmjC-HDMs (KDM4A/C/E) display hydroxylase 
or demethylase activity toward ARK+(Nε- methyl bis(propargyl))ST. Briefly, the holoenzyme was 
incubated with necessary reaction components (buffer, αKG, ascorbic acid) and 400 µM peptide for 
up to one hour at room temperature.  For all three enzymes, the t = 0 min spectra are nearly 
identical to the t = 60 min spectra (Appendix B). Dominant peaks in each spectrum correspond to 
the starting material and its sodium adduct, as well as ARK+(Nε- methyl mono(propargyl))ST at     
[M - 38]+. The KDM4C t = 0 min and t = 60 min spectra are given as representatives in Figure 4.7. 
The mono-propargyl peak does not grow with time, and we find no peaks corresponding to 
demethylation [M – 14]+ or hydroxylation [M + 17]+.  
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Figure 4.7. MALDI-TOF spectra obtained from KDM4C incubation with ARK+ST for (left) 0 
minutes and (right) 60 minutes.  
  
It is unclear as to why not one of our HDMs, and KDM4C in particular, displays 
demethylase or hydroxylase activity toward ARK+(Nε- methyl bis(propargyl))ST. We know from the 
literature that KDM4 enzymes show no detectable activity toward the H3K9 substrate 
ARK+me1STGGK, most likely due to orientation of the lone methyl group away from the      
Fe(IV)-oxo active species.4 The bulkiness of the propargyl groups in our inhibitor may prevent 
proper orientation of the ARK+(Nε- methyl bis(propargyl))ST methyl group needed for 
demethylation to take place. Moreover, hydroxylation at the propargyl methylene groups may not 
occur owing to these carbons being too far from or too close to the Fe(IV)-oxo species. 
Modification of ARK+(Nε- methyl bis(propargyl))ST could lead to effective specific inhibitors of 
JmjC-HDMs, because this peptide does not act as a substrate and will not be consumed in the 
reaction, thereby retaining its inhibitory effectiveness.  
 Finally, both ARK(Nε- bis(propargyl))ST and the methylated peptide were used to test in situ 
Huisgen 1, 3- dipolar cycloaddition with KDM4A and KDM4C iron- and nickel-azide complexes. 
ARK+(Nε- bis(propargyl))ST 
ARK+(Nε- mono(propargyl))ST 
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Briefly, 250 µM HDM was incubated with 1 equivalent metal salt (Fe(II) or Ni(II)), αKG, NaCl, 3 
equivalents modified ARKST peptide, and 200 mM sodium azide. The high concentration of azide 
is necessary owing to apparent low affinity of N3
- for our HDM/Fe complexes. As shown in Figure 
4.8, azide is a very weak inhibitor of KDM4A and KDM4C, with IC50 values greater than 10 mM.    
 
Figure 4.8. N3
- is a weak inhibitor of KDM4A and KDM4C, as shown by MALDI-TOF MS.  
  
Varying conditions were used to test for triazole formation: 1) varying temperature (4, 20, 
and 37 °C), 2) varying amounts of time (4 – 24 h), and 3) varying metal salt (Fe and Ni) for 
holoenzyme generation. From earlier model studies in our group, we know that nickel and cobalt are 
more effective at click chemistry than iron; unfortunately, our purified HDMs precipitate upon 
reconstitution with cobalt salts.24  
ESI-MS and MALDI-TOF MS analyses reveal no evidence of triazole formation by using 
either ARK(Nε- bis(propargyl))ST or the methylated peptide with KDM4A or KDM4C. MALDI 
analysis of KDM4C samples with Fe or Ni and ARK+(Nε- methyl bis(propargyl))ST are given as 
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representatives in Figure 4.9. The m/z values corresponding to potential peaks of interest are given 
in Table 4.2. Note that following spotting of samples purified by C18 or SCX Zip Tip on the MALDI 
plate, an overlay of ARKme3STGGK (m/z 846) in matrix was used for calibration purposes.  
 
Table 4.2. ARK+(Nε- methyl bis(propargyl))ST peaks of interest in the enzyme-templated 
cycloaddition experiment. 
Species m/z of Interest 
Starting material M1+ = 652.4 
Demethylated M1+ = 638.4 
Mono-triazole M1+ = 695.4 
Di-triazole M1+ = 738.4 
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Figure 4.9. MALDI-TOF MS results for (top) KDM4C-Fe-azide and (bottom) KDM4C-Ni-azide 
incubations with ARK+(Nε- methyl bis(propargyl))ST.  
ARK+(Nε- methyl bis(propargyl))ST 
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 Since we have evidence of KDM4A and KDM4C inhibition by our modified H3K9 
peptides, potential explanations as to why we find no enzyme-driven triazole formation in any of our 
experimental setups are varied. One reason may be due to weak enzyme-metal-azide adduct 
formation, a variable over which we have no control. A second reason could be due to poor 
orientation of the propargyl groups within the active site that leads to improper interaction with the 
metal center. For instance, the azide-iron bond length, which a previous study found to be 2.3 Å in a 
diferrous protein,25 may not be appropriate for any triazole formation to take place, with the 
propargyl C≡C predicted to be at between 4 – 5 Å from the metal center. There may not be enough 
room in the KDM4 active site to accommodate the Lys-Nε alkyl groups in addition to the metal-
azide adduct, if it does indeed form. Keeping the Lys propargyl groups, but shortening the Lys side 
chain by one or two methylene groups could offer a potential remedy if the issue is crowding within 
the KDM4C active site.   
4.4 Conclusions 
 In conclusion, we have developed two novel histone H3 peptides in an effort to selectively 
inhibit the H3K9/H3K36 HDM KDM4C over the closely related KDM4A. The two 5-mers come 
from residues 7-11 on histone 3, ARKST, with the Lys residues modified to incorporate two 
propargyl groups on the terminal nitrogen, with one of the peptides having an additional methyl 
group on the terminal nitrogen to make it quaternary. We find selective, albeit weak, inhibition of 
KDM4C over KDM4A using the unmethylated peptide ARK(Nε- bis(propargyl))ST. Using the 
methylated peptide ARK+(Nε- methyl bis(propargyl))ST, we find a near 3-fold increase in the 
inhibition of KDM4C, and unexpectedly, a similar level of inhibition of KDM4A. The obtained Ki
app 
values reflect the difficulty in achieving potent inhibition of JmjC-HDMs by small molecules that do 
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not chelate the active site metal center. We find that none of our three KDM4 enzymes display 
hydroxylase or demethylase activity toward either modified H3 peptide, suggesting that these 
peptides could offer a starting point in the design of effective specific inhibitors of JmjC-HDMs. 
Furthermore, we find no evidence of triazole formation in KDM4-driven cycloaddition studies with 
either of our modified peptides, suggesting once more that these enzymes may not be well suited for 
enzyme-templated Huisgen 1, 3- dipolar cycloaddition reactions. 
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Chapter 5: Inhibition and Crystallography 
Studies of KDM4A with the Small Molecule 
JIB-04 
 
5.1 Introduction 
The small molecule JIB-04 is the first reported specific pan-selective inhibitor of JmjC-
domain containing histone demethylases (JmjC-HDMs). From a cell-based assay screening of 2,080 
compounds, the pyridine hydrazone was identified as an epigenetic modulator.1 JIB-04 has two 
forms, the E- and Z- isomers, as shown in Figure 5.1. The study found only the E- isomer to be 
active in cell-based assays, with the Z- isomer up to 100-fold less potent. To test the inhibition of 
histone-modifying enzymes, the authors used three in vitro methods when appropriate: a 1H-NMR 
assay, utitlizing the signal intensity of the trimethyl H3K9me3 peak; a formaldehyde dehydrogenase 
(FDH) coupled assay, wherein the oxidation of the demethylation reaction side product 
formaldehyde is coupled with the reduction of NAD+ to the fluorescent NADH; and lastly, direct 
western analyses of a full-length histone H3 substrate. Furthermore, the anticancer potential of   
JIB-04 was tested, as the activities of JmjC-HDMs become deregulated in various cancers. The 
inhibitor consistently displayed specificity of action in cancerous cells over patient-matched healthy 
cells.  
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Figure 5.1. JIB-04 (left) E- and (right) Z- isomers.  
 
The published study finds JIB-04 to slow the activities of a broad range of JmjC-HDMs, 
with the E- isomer displaying its most potent inhibition on the pure H3K4me3 (KDM5A) and 
H3K9me3 demethylases (KDM4D-E), with lesser action against the H3K27 (KDM6B) and mixed 
H3K9/H3K36 demethylases (KDM4A-C). Reported IC50 values range from 200 nM to 1.1 µM, 
which scale to what we find in the present study using alternative enzyme and substrate 
concentrations (vide infra).  Importantly, JIB-04 does not show action against the related αKG-
dependent prolyl hydroxylases (PHDs) and TET enzymes or other chromatin-modifying enzymes 
such as histone deacetylases (HDACs). 
With the exception of a natural product named Tripartin, JIB-04 is the first specific inhibitor 
of JmjC-HDMs that is not a competitor of α-ketoglutarate.2 While the authors find JIB-04 to be 
competitive with the primary histone substrate instead, the exact mode of inhibition was unclear. No 
crystal structure of a JmjC-HDM in complex with JIB-04 had been solved, nor were there any 
experiments done that might elucidate if JIB-04 is competitive with O2 in addition to the histone 
substrate.  
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The present study examines the inhibition of the mixed H3K9/H3K36 demethylase 
KDM4A with respect to the cosubstrate O2 by determining IC50 values at three concentrations of O2 
using a real-time dioxygen consumption assay. Molecular modeling studies of the JIB-04 E- and Z- 
isomers in the KDM4A active site reveal the potential basis for the isomer-specific inhibition. 
Finally, a binary complex of the catalytic core of KDM4A with JIB-04 was resolved, revealing only a 
portion of the inhibitor in the KDM4A active site.  
 
5.2 Methods 
5.2.1 Synthesis of JIB-041  
N
Cl
HN
NH2
+
N
O
2-propanol
Conc. H2SO4
N
N
NH
N
Cl  
5-chloro-2-hydrazinopyridine (50 mg, 0.35 mmol, 1 equiv.) and 63.8 mg 2-benzoylpyridine 
(0.35 mmol, 1 equiv.) were dissolved in 2.1 mL 2-propanol and set to stir at room temperature. 
Hydrochloric acid (1.75 mmol, 5 equiv.) was added dropwise, and the solution was heated to 50 °C 
in an oil bath. The reaction was monitored by TLC in ethyl acetate; once complete, the solution was 
cooled to room temperature and neutralized using saturated sodium bicarbonate solution. The 
resulting precipitate was vacuum dried at 60 °C for 12 hours; monohydrate pale golden powder, 30:1 
E- : Z- isomer, 78.6 mg, 0.24 mmol, 68% yield.  1H NMR ((CD3)2SO), δ: 8.83 (d, 1H), 8.44 (s, 1H), 
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8.20 (m, 1H), 8.13 (s, 1H), 7.84 (m, 2H), 7.55 (m, 4H), 7.35 (s, 3H). 13C NMR (CDCl3), δ: 155.93, 
154.68, 149.30, 146.94, 146.19, 138.07, 136.21, 131.72, 129.75, 129.02, 123.15, 122.92, 121.23, 
108.73. See Appendix C for NMR spectra. ESI-MS m/z 309.1 (calculated), m/z 309.1 
(experimental).  
 
5.2.2 Inhibition of KDM4A by JIB-04 
JIB-04 has limited solubility in aqueous solution, so inhibitor stock solutions were made in 
DMSO. The overall volume of DMSO in any given reaction solution was kept at 0.1%, as DMSO 
inhibits KDM4A at higher concentrations. In addition, when testing concentrations of JIB-04 
greater than 20 µM, it was necessary to include 0.01% Tween-20 in order to keep JIB from 
precipitating out of the buffered reaction solutions.  
 
MALDI-TOF Mass Spectrometry Inhibition Assays 
KDM4A was tested for inhibition by the small molecule JIB-04 using the discontinuous 
MALDI-TOF MS assay. Purified KDM4A (8 µM) was incubated with 8 µM FeII(NH4)2SO4·6H2O 
and, if  a pre-incubation trial, 0-500 µM JIB-04 in DMSO. Pre-incubation trials allowed for five 
minutes of  pre-incubation on ice before the reaction was started by the addition of  a solution 
containing 80 µM H3(7-14)K9me3 in 50 mM HEPES (pH 7.5), 500 μM sodium L-ascorbate, and     
300 µM αKG. The reaction was allowed to proceed at 37 °C for 20 minutes. The enzymatic 
demethylation was stopped by addition of  MeOH and TFA, the precipitated protein is removed via 
centrifugation, and the resulting supernatant is collected. An aliquot of  the reaction solution was 
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added to 10 mg/mL α-cyano-4-hydroxycinnamic acid MALDI matrix in 50% acetonitrile/0.1% TFA 
and spotted directly onto the MALDI plate. For analysis, an ABI DE-STR MALDI TOF instrument 
was used.  
Percent demethylation values were determined using the relative intensities of  the mono-,  
di-, and tri-methylated H3(7-14)K9 peaks in the following equation (5-1): 
                 
                  
                        
           (5-1) 
O2 Consumption Inhibition Assays 
 KDM4A was tested for inhibition by the small molecule JIB-04 using the O2 consumption 
assay. The reaction solution containing 50 mM HEPES (pH 7.5), 300 µM αKG (pH 7.5), 500 µM 
sodium L-ascorbate, 100 µM H37-14K9me3 , and ± JIB-04 (in DMSO) was equilibrated 2 – 5 min 
under an atmosphere of varying O2 concentration. Following equilibration, the electrode was 
lowered into the reaction solution, and a 4 min background O2 consumption reading was allowed. 
Separately, purified KDM4A (2 µM) was reconstituted with FeII(NH4)2SO4·6H2O (2 µM) and, if a 
pre-incubation trial, to the holoenzyme was added JIB-04 in DMSO (0 – 20 µM) for a pre-
incubation time of approximately 1 min. In pre-incubation trials, the volume of DMSO added to the 
KDM4A/Fe aliquot was 1 µL (less than 20% of the HDM/Fe aliquot volume, and 0.1% of the 
reaction volume). The reaction was started by the addition of KDM4A/Fe/± JIB-04 to the O2 
electrode chamber. All final rates were calculated by subtracting background oxygen consumption 
due to ascorbate and the holoenzyme in the absence of peptide substrate. 
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 IC50 values were determined by fitting the inhibition data to the sigmoidal dose-response 
(variable slope) equation (5-2) using the program GraphPad Prism, where “top” and “bottom” are 
the y-values at the top and bottom plateaus:  
          
            
                        
      (5-2) 
5.2.3 Docking Studies of KDM4A with JIB-04 Isomers  
Low energy conformers of JIB-04 E- and Z- isomers were generated using OMEGA 
following minimization by SZYBKI (both OpenEye). The conformers were modeled into the 
KDM4A active site (PDB 2Q8C) with OpenEye’s FRED fast exhaustive docking program using the 
Poisson-Boltzmann solvation method at 310 K, taking into account cavity solvation energies. All 
renderings were generated using PyMol.  
5.2.4 Crystallography 
Protein crystals were grown by the hanging drop vapor diffusion method at 4 °C. Crystals of 
KDM4A (12 mg/mL) in complex with JIB-04 (750 µM) formed in drops of a 1:1 mixture of protein 
and crystallization buffer (0.1 M citrate pH 6.0, 17.5% PEG-3500, 4 mM NiCl2 or 
FeII(NH4)2SO4·6H2O). Crystals were harvested from the mother liquor with a nylon loop, mounted 
on a goniometer, and directly frozen in a liquid N2 vapor stream at 100 K.  Data were collected by 
Dr. Soon Goo Lee using 19ID beamline at Argonne National Laboratory Advanced Photon Source 
with a CCD detector at a distance of 327.18 mm from the crystal.  Images (180 frames) were 
collected at 0.979Å in 1.0°oscillations (a 180° hemisphere), indexed (P 2 21 21), and scaled using 
HKL 3000.3  This resulted in 14,068 reflections in the 50 - 3.2 Å resolution range. Unit cell 
parameters and data reduction statistics are summarized in Table C.1 in Appendix C.  
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Detector CCD 
Type ADSC QUANTUM 315r 
Details Rosenbaum-Rock high-resolution double-crystal monochromator 
 
The structure of KDM4A was phased by using the molecular replacement method with 
Phaser and a model of the crystal structure of KDM4A complexed with inhibitor (PDB: 3RVH) 
structure.4  Based on the Matthew’s coefficient, two protein monomers were expected in the 
asymmetric unit.  The solution from Phaser had a top TFZ of 17.6. Manual fitting was initiated 
using COOT.5 Refinement was performed using Phenix with 10% of the data excluded from 
refinement for the Rfree calculation.
6, 7 The structure models were analyzed at TLS Motion 
Determination Server and refined with eight TLS groups, yielding a model with an Rcryst of 21.8% and 
Rfree of 29.1%.
8  The final model was analyzed using the CCP4 programs SFCHECK and 
PROCHECK.9, 10, 11   Refinement statistics are listed in Table C.1 in Appendix C.  
 
5.2.5 Stability of JIB-04 in Aqueous Solution 
The stability of JIB-04 in aqueous solution was tested at pH 6.0 (50 mM Citrate) and pH 7.5 
(50 mM HEPES), as pH 6.0 citrate buffer was used for protein crystallization, and pH 7.5 HEPES 
was the buffer used in the MALDI-TOF MS and O2 consumption assays. ESI-MS scan range of m/z 
100 – 500 shows JIB-04 [M + H]+ and [M + Na]+ peaks. When the same samples were tested three 
days later, the only peaks seen are [M + H]+ and [M + Na]+. Thus, JIB-04 appears to be stable in 
aqueous solution.  
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Next, the stability of JIB-04 was tested in the presence of KDM4A. Testing conditions: 60 µM 
KDM4A, 60 µM FeII(NH4)2SO4·6H2O, 300 µM JIB-04, 0.01% Tween-20, 50 mM HEPES pH 7.5 or 
Citrate pH 6.0. Small portions of each sample were removed at various times and diluted 2x with 5 
mM EDTA in HEPES buffer. Then, the protein was precipitated with MeOH and the supernatant 
was analyzed by ESI-MS. After five days at 4 °C, JIB appeared to be stable in the presence of 
KDM4A.  
 
5.3 Results and Discussion 
 The small molecule JIB-04 is made up of several pyridine moieties and a hydrazone group 
that together selectively inhibit multiple JmjC-HDMs in an isomer-specific fashion. As JIB-04 shows 
remarkable action in promoting cell death in cancerous cells over patient-matched healthy cells, and 
does not alter the activities of related enzymes such as the αKG-dependent PHDs and TET 
enzymes, understanding the inhibitor’s mode of action is an active area of interest.  
 Initially, we were interested to see how JIB-04 affected the activity of the H3K9/H3K36 
HDM KDM4A as shown through two of our in vitro assays. KDM4A was first tested for inhibition 
by JIB-04 without pre-incubation of the holoenzyme and inhibitor using the O2 consumption assay. 
Briefly, KDM4A (2 µM) was reconstituted with Fe(II) (2 µM) prior to injection into the reaction 
chamber containing αKG (300 µM), ascorbic acid (500 µM), H3(7-14)K9me3 (100 µM), HEPES      
(pH 7.5, 50 mM), Tween-20 (0.1%), and JIB-04 in DMSO (0 – 500 µM). The obtained plot shown in 
Figure 5.2 displays a modest decrease in enzymatic activity when JIB-04 is present in the reaction 
solution. The inhibitory effect seems to level off at !100 μM JIB-04, which is likely due to the 
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insolubility of JIB-04 in aqueous solution at high concentrations, even with the addition of the 
solubilizing agent Tween-20.  

 
Figure 5.2. Mild inhibition of KDM4A by JIB-04 as shown by the O2 consumption assay. 
 
It is worth noting that the initial report of JIB-04 was vague concerning the in vitro 
inhibition assay conditions.1  The authors report an IC50 of 445 nM when using a KDM4A 
concentration of 206 nM. However, the authors do not specify the concentration of H3K9me3 
peptide used, nor do they specify the length of peptide used, and both of these variables would 
affect IC50 values. Assuming that the common octapeptide H3(7-14)K9me3 was used, a 1:6.5 ratio of 
KDM4A:H3K9me3 is calculated (400 ng KDM4A ≈ 9.1e-9 mmol, 50 ng H3(7-14)K9me3 ≈ 5.9e-8 
mmol). In our preliminary O2 consumption study, a 1:50 ratio of KDM4A:H3(7-14)K9me3 was used, 
from which we obtain Figure 5.2. Since JIB-04 is a putative histone peptide substrate competitor, we 
can reasonably expect a lower level of inhibition than that found in the published study. The low 
level of inhibition found when JIB-04 is added to the reaction solution, as opposed to the 
holoenzyme directly for pre-incubation, was further confirmed by a discontinuous MALDI-TOF 
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MS assay (Figure C.1 in Appendix C). Moreover, we find the same level of inhibition when using 1:1 
KDM4A:Fe(II) or an excess of Fe(II) to produce the holoenzyme, indicating that the low level of 
inhibition is not due to JIB-04 interacting with excess iron in solution.   
 Next, the inhibition of KDM4A was tested using the MALDI-TOF MS assay, allowing for 
pre-incubation of the holoenzyme with JIB-04 (Figure 5.3). Briefly, KDM4A (8 µM) was 
reconstituted with one equivalent Fe(II) salt, then JIB-04 (0-500 µM) was added, and the mixture 
was allowed to incubate for several minutes. Then the reaction is started by the addition of αKG,      
H3(7-14)K9me3 and ascorbic acid. Using this method, we find substantial inhibition of the enzyme, 
with an IC50 of approximately 20 µM (logIC50 = -4.67 ± 0.01). This level of inhibition is in line with 
that found for KDM4A in the published study, as scaling from the 206 nM KDM4A used in the 
study to the 8 μM KDM4A used in this research, it is reasonable to expect an IC50 near 20 μM.  
  
Figure 5.3. Inhibition of KDM4A by JIB-04 following pre-incubation with holoenzyme, as found by 
MALDI-TOF MS.    
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Having confirmed that pre-incubation of the holoenzyme with JIB-04 was necessary for 
substantial inhibition of KDM4A, the inhibition was screened at three different concentrations of 
O2 using the dioxygen consumption assay. The inhibition screen was done in an effort to see 
whether the inhibition by JIB-04 is O2-dependent. A stronger inhibitory effect at low concentrations 
of O2 could signify that JIB-04 interacts with the KDM4A active site metal center in a similar 
manner as O2. Briefly, reaction components (buffer, αKG, H3(7-14)K9me3, reducing agent) are 
equilibrated under varying atmospheres of O2, while outside the reaction vessel, the holoenzyme is 
incubated with JIB-04 (0 - 20 µM). Injection of the HDM/Fe/JIB-04 complex into the reaction 
solution marks the start of the reaction. The concentrations of O2 chosen are as follows: 258 µM 
(the concentration of O2 in air-saturated water), 1200 µM (O2-saturated water), and 60 µM             
(≈ Km(O2)for KDM4A). The KDM4A activities and corresponding IC50 plots at the three 
concentrations of O2 are given in Figure 5.4.  
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Figure 5.4. Inhibition of KDM4A by JIB-04 as tested at three concentrations of O2.  
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 Interestingly, with decreasing O2 concentration we find decreasing IC50 values, and thus 
increasing potency of JIB-04 inhibition (60 µM O2: logIC50 = -5.256 ± 0.009; 258 µM O2: logIC50 = -
4.81 ± 0.06; 1200 µM O2: logIC50 = -4.7 ± 0.1). We find a nearly 3-fold increase in inhibition when 
going from 258 to 60 µM O2. Unfortunately, experimental limitations prohibit the testing of the 
inhibition at truly low concentrations of O2, as KDM4A exhibits little enzymatic activity at 
concentrations less than 60 µM. The discrepancy between the IC50’s found in air-saturated water 
(258 µM O2) for the MALDI-TOF assay (Figure 5.3, IC50 ≈ 20 µM) and the O2 consumption assay 
(IC50 of 15.5 µM) is likely due to varying experimental conditions, with the O2 consumption assay 
giving a more accurate representation of enzymatic activity and inhibition.  The IC50 values at       
258 µM and 1200 µM are similar within experimental error, as would be expected since both of 
these O2 concentrations are significantly higher than the Km(O2) for KDM4A. While a true measure 
of the inhibitor’s competition with O2 could be found by obtaining O2 Km plots at varying 
concentrations of JIB-04, the varying IC50 values obtained at the three O2 concentrations provide 
evidence that JIB-04 potentially disrupts O2 binding in the KDM4A active site.  
Molecular modeling studies of the JIB-04 E- and Z-isomers provide further support as to 
the mode of inhibition of KDM4A (Figure 5.5). Importantly, both JIB-04 isomers were docked into 
the KDM4A active site without ligand-guided assistance. Ligand-guided docking uses the electron 
density of and chemical complementarity to known bound ligands to aid in the virtual screening of 
molecular poses.12 Thus, the shape of the histone peptide substrate was not used to guide the 
modeling of either JIB-04 isomer. As seen in Figure 5.5, the aromatic moieties of only the E-isomer 
orient themselves in such a way as to mimic the projection of the natural H3K9me3 substrate into 
the KDM4A active site. Therefore, the predicted energetically favorable fit for the JIB-04 E-isomer 
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is in place of the histone substrate, which helps to explain the isomer-specific inhibition of JmjC-
HDMs by this compound. 
 
Figure 5.5. (left) JIB-04 E-isomer (pink sticks) competes with the histone peptide substrate (green 
sticks) in the KDM4A active site, with H2O shown as red sphere (PDB 2Q8C); (right) JIB-04 Z-
isomer is a weak inhibitor of KDM4 enzymes, as it does not compete with the peptide substrate.  
 
 A closer look at the binding of the E-isomer is depicted in Figure 5.6. We find that the 
chlorine of this isomer points toward the metal center in a manner similar to the NMe3
+ group, 
which would make it the most likely portion of the inhibitor to affect O2 binding. The Ni(II) – Cl 
distance (4.8 Å) as modeled is substantially longer than that found in the obtained crystal structure 
(vide infra). Both pyridine nitrogens and the hydrazone group are predicted to form hydrogen bonds 
with Lys 241 at 3.1 Å and 2.7 Å, respectively, while the hydrazone group could form an additional 
hydrogen bond with Asp 191, at 2.9 Å. We find no evidence of π-π stacking interactions to stabilize 
JIB-04 binding, as the nearest aromatic residue, Tyr 175, is slightly displaced and over 5 Å away.  
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Figure 5.6. (a) View of JIB-04 E-isomer as modeled in the KDM4A active site. KDM4A shown as 
transparent ribbons and green sticks; JIB-04 shown as pink sticks, with the chlorine colored green. 
Ni(II) (orange sphere) replaces Fe(II) in the active site, and structural Zn(II) is shown as a blue 
sphere. (b) Close-up view of JIB-04 modeled in the KDM4A active site, showing predicted polar 
contacts with Asp 191 and Lys 241. 
a. 
b. 
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Crystallization of JIB-04 with KDM4A was attempted, and a crystal structure of a JIB-04 
fragment in complex with the catalytic core of KDM4A (residues 1-349) was obtained to 3.1 Å 
resolution (Figure 5.7 and Table C.1 in Appendix C). No αKG or αKG analog was added to the 
crystallization solution to ensure that there was no bias in JIB-04 binding, and therefore the complex 
is binary. Refinement of the obtained structure made clear that JIB-04 was not present in its whole 
form. Rather, the ligand electron density is a bit ambiguous, and could be accounted for by only a 
portion of the inhibitor, predicted to be 2-amino-5-chloropyridine, as shown in Figure 5.7.  
 
Figure 5.7. The experimental 2Fo ─ Fc electron density, displayed as blue mesh, is shown for the 
ligand fragment in two alternate views.  
 
As only a fragment of JIB-04 was determined to be in complex with KDM4A in the crystal 
structure, JIB-04’s susceptibility to hydrolysis or decomposition was tested in two ways. Briefly,   
JIB-04 was tested for stability in citrate pH 6.0 and HEPES pH 7.5 buffers up to two weeks at 4 °C, 
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with no evidence of decomposition via analysis by ESI-MS. Next, JIB-04 was tested for stability in 
the presence of KDM4A/Fe(II) and citrate pH 6.0 or HEPES pH 7.5 buffers at 4 °C for up to five 
days, with no evidence of decomposition. As the stability of JIB-04 was not tested in the presence of 
KDM4A/Ni(II), it is possible that the nickel-containing HDM catalyzed the hydrolysis of JIB-04 
and cleavage of the hydrazone N-N bond during the crystallization.  
While a higher resolution structure would help to confirm 2-amino-5-chloropyridine as the 
portion of JIB-04 that can be accounted for in the crystal structure, we can go forward and compare 
the crystallography results with those of the docking study. We find that the inhibitor fragment 
chelates to the metal center through its chlorine, as shown in Figure 5.8. Notably, the Cl – Ni(II) 
distance found in the crystal structure (2.4 Å) is substantially smaller than that predicted from the 
docking study (4.8 Å). Moreover, the orientation of the JIB-04 fragment is quite different in the 
crystal structure when compared to the docking results. Instead of the pyridine nitrogen and           
2-amino group forming predicted polar contacts with Asp 191 and Lys 241, we find a single, weak 
hydrogen bond (3.5 Å) between the 2-amino group and Tyr 132, plus a potential weak aromatic 
interaction with Phe 185 (4.4 Å).  
 
 
 
 
 
 
129 
 
 
 
Figure 5.8. (a) View of the KDM4A:JIB-04 fragment crystal structure. KDM4A shown as 
transparent ribbons and green sticks; the JIB-04 fragment shown as gray sticks, with the chlorine 
colored green. Ni(II) (orange sphere) replaces Fe(II) in the active site, and structural Zn(II) is shown 
as a blue sphere. (b) Close-up view of the JIB-04 fragment in the KDM4A active site, showing 
hydrogen bonding to Tyr 132 and chelation to Ni(II). 
a. 
b. 
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It is difficult to know if the information obtained from the structural experiment is in 
agreement with what happens with the inhibitor in situ. However, if JIB-04 does indeed hydrolyze in 
the presence of KDM4A, as seen in the crystal structure, the short Ni(II) – Cl distance could lead to 
altered O2 binding in the active site, as suggested by our O2 competition study (Figure 5.4). The 
orientation of the JIB-04 fragment in the crystal structure does not appear to be competitive with 
the histone H3 substrate, in disagreement with what the published study concluded and our docking 
studies predicted. It is important to note that the protein crystals were formed in the absence of the 
cosubstrate αKG or the amide analog N-oxalylglycine (NOG), while the molecular modeling study 
was done with a KDM4A/Ni(II)/αKG/H3K9me3 complex. Obtaining another crystal structure in 
the presence of αKG or NOG could help resolve some of the discrepancies encountered in the 
present study. 
5.4 Conclusions 
 In conclusion, we have examined the inhibition of KDM4A by the small molecule JIB-04 
with respect to the cosubstrate O2. We find that the inhibition by JIB-04 increases with decreasing 
O2 concentration. Varying IC50 values at different O2 concentrations suggest that JIB-04 may inhibit 
KDM4A in part by disrupting the binding of O2. The E- and Z- isomers of JIB-04 were modeled 
into the KDM4A active site, revealing that the aromatic moieties of the E- isomer are predicted to 
orient themselves in a way that mimics the natural projection of the histone H3 substrate into the 
enzyme active site. Lastly, a 3.1 Å crystal structure of the catalytic core of KDM4A in complex with 
JIB-04 was solved, and the ligand electron density is accounted for by only a portion of the inhibitor. 
Future studies might focus on obtaining higher resolution crystal structures of KDM4A in complex 
with JIB-04, both with and without αKG or the amide analog NOG.   
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Chapter 6: Conclusions and Future Directions 
  
The JmjC domain-containing HDMs are αKG-dependent, O2-activating, non-heme iron 
enzymes. At the start of this dissertation work, little was known of the enzymology of the KDM4 
subfamily of HDMs. This work focused on three members of the KDM4 subfamily: the mixed 
H3K9/H3K36 demethylases KDM4A and KDM4C and the pure H3K9 demethylase KDM4E. 
KDM4A and KDM4C were of particular interest, as these enzymes have been implicated in 
numerous cancers, while KDM4E was studied for its similarity to KDM4D, an enzyme responsible 
for the regulation of the tumor suppressor p53.1-4  The major goals of this dissertation work were to 
develop an understanding of the in vitro kinetics and inhibition of our three JmjC-HDMs, as well as 
to develop a continuous, real-time enzymatic assay to monitor the activity of our HDMs.   
Initially, we achieved a detailed kinetic analysis of our HDMs using three enzyme activity 
assays, including a novel continuous O2 consumption assay. From our studies, we propose that 
members of the KDM4 subfamily may act as O2 sensors in vivo due to their low apparent affinities 
for O2. Also from this initial study, we found that the co-substrate αKG inhibits KDM4C, with 
KDM4C displaying its optimal activity in vitro at αKG concentrations found in cancer cells. Future 
studies of the KDM4 subfamily should focus on the in vivo implications of the observed αKG 
substrate inhibition. As a complement to this study, crystallization of the catalytic core of KDM4C 
with a large excess of αKG should be attempted, to see if two molecules of αKG bind in the 
KDM4C active site.  
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Early in this work, a small library of simple molecules was synthesized in an effort to identify 
potential scaffolds for JmjC-HDM inhibition. The molecules were designed to mimic the primary or 
secondary substrates, by the inclusion of dimethylamino or trimethylammonium groups or amide 
oxalyl groups, respectively. Furthermore, the molecules included carbon-carbon triple bonds or the 
corresponding 1,2,3-triazole group, as we proposed that the triazole-containing compounds would 
be more potent inhibitors, due to the KDM4 low apparent affinities for O2. From this study, we 
learned that the inhibition of JmjC-HDMs is a difficult task, as recognition of the primary substrate 
is due to multiple histone H3 main-chain contacts with the enzyme. Also from this study, we found 
no evidence of KDM4-driven triazole formation using any of our alkyne-containing small molecules. 
Future studies can focus on the modification of our most promising analogs, the 
trimethylammonium- and ester- containing 5 and 6 (Figure 6.1), toward the development of specific 
inhibitors of JmjC-HDMs. These compounds should be screened against other αKG-dependent 
oxygenases, such as to confirm their specificity. An additional study could test whether the triazole-
containing 6 is competitive with O2, using our developed O2 consumption assay.   
-I+Me3N O
O N
N
NH
O
O
-I+Me3N
5
6  
Figure 6.1. Two inhibitors of KDM4E, as described in Chapter 3. 
 A peptidomimetic approach was taken in a second study of JmjC-HDM inhibition. Two 
histone H3(7-11) peptides were synthesized, with modified Lys residues. We find                    
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ARK(Nε-bis(propargyl))ST to be selective for KDM4C over KDM4A, as predicted. Stronger, but 
less selective, inhibition came with the positively charged ARK+(Nε- methyl bis(propargyl))ST. Our 
three JmjC-HDMs showed no hydroxylase activity toward either peptide. One possible direction in 
the modification of ARK+(Nε- methyl bis(propargyl))ST to make it a stronger KDM4C inhibitor 
might be in the shortening of the Lys side chain by one or two methylene groups, to account for the 
length of the propargyl groups. Future studies should test ARK+(Nε- methyl bis(propargyl))ST and 
all modified peptides for specificity against other JmjC-HDMs, such as PHF8. 
 Testing of the KDM4 subfamily members with a multitude of alkyne-containing substrates 
in enzyme-templated Huisgen 1,3-dipolar cycloaddition reactions has given no evidence of enzyme-
driven 1,2,3-triazole formation. From these studies, we conclude that JmjC-HDMs are not suitable 
“vessels” for in situ cycloaddition reactions, likely due to the low affinity of azide for the HDM 
metal center.   
Our final study of KDM4 inhibition was with the pan-selective JmjC-HDM inhibitor JIB-04. 
We found that the inhibition of KDM4A by JIB-04 increased with decreasing O2 concentration, 
suggesting that JIB-04 may work in part by altering the binding of O2 to the Fe(II) metal center. A 
published study found the JIB-04 E-isomer to be competitive with the H3K9 substrate, and our 
docking studies agreed. A 3.1 Å crystal structure of KDM4A in complex with Ni(II) and JIB-04 
revealed only a portion of the inhibitor, predicted to be 2-amino-5-chloropyridine, to be bound in 
the enzyme active site. This surprising result should be confirmed by additional crystallography 
studies. Future studies should focus on obtaining a higher resolution structure of JIB-04 in complex 
with KDM4A, both with and without αKG or NOG.  
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Table A.1.  Data collection and refinement statistics for KDM4A/Ni2+/αKG.a 
Resolution range (Å…) 35.15  - 2.093 (2.168  - 2.093) 
Space group P 2 21 21 
Unit cell 57.143 101.122 149.028 90 90 
90 
Unique reflections 50379 (4412) 
Completeness (%) 97.34 (86.85) 
Mean I/sigma(I) 15.20 (4.11) 
Wilson B-factor 23.48 
R-work 0.1812 (0.2122) 
R-free 0.2236 (0.2598) 
Number of non-hydrogen 
atoms 
6125 
  macromolecules 5735 
  ligands 24 
  water 366 
Protein residues 699 
RMS(bonds) 0.005 
RMS(angles) 0.93 
Ramachandran favored (%) 98 
Ramachandran outliers (%) 0 
Clashscore 6.07 
Average B-factor 35.00 
Macromolecules 34.70 
Ligands 31.50 
Solvent 39.20 
a Statistics for the highest-resolution shell are shown in parentheses. 
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A.1. MALDI-TOF MS Assay 
a) 
 
 
 
[H3(7-14)K9me3]
+
 
[H3(7-14)K9me2]
+
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b) 
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[H3(7-14)K9me3]
+
 
141 
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+
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[H3(7-14)K9me2]
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[H3(7-14)K9me3]
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Figure A.1. KDM4C demethylase activity and substrate inhibition by αKG, as monitored by 
MALDI-TOF MS: a) ~0 minute reaction time, b) 10 minute reaction time with 50 μM αKG, c) 10 
g) 
f) 
[H3(7-14)K9me2]
+
 
[H3(7-14)K9me3]
+
 
[H3(7-14)K9me2]
+
 
[H3(7-14)K9me3]
+
 
143 
 
minute reaction time with 100 μM αKG, d) 10 minute reaction time with 300 μM αKG, e) 10 
minute reaction time with 1 mM αKG, f) 10 minute reaction time with 3 mM αKG, g) 10 minute 
reaction time with 5 mM αKG. 
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Appendix B: Supplementary Information for 
Chapter 4 
 
1H-NMR of Boc-Lys(Nε- bis(propargyl)-OMe in CDCl3: 
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13C-NMR of Boc-Lys(Nε- bis(propargyl)-OMe in CDCl3: 
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ESI-MS of ARK(Nε- bis(propargyl))ST: [M+H]+ = 638.3; [M-H+2Na]+ = 682.3 
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MALDI-TOF MS of ARK(Nε- bis(propargyl))ST: 
 
 
 
 
 
 
 
 
 
 
 
 
ARK(Nε- mono(propargyl))ST 
ARK(Nε- bis(propargyl))ST 
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ESI-MS of methylated ARK+(Nε- methyl bis(propargyl))ST: 
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149 
 
ESI-CID-MS/MS: 
Note: absent from the spectrum is a peak at 260, which would correspond to AR(methylated) 
 
 
06262014-Barrie-peptide-MS2 #502-525 RT: 1.95-2.25 AV: 24 NL: 1.04E6
F: ITMS + p ESI Full ms2 326.82@cid0.00 [85.00-2000.00]
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06262014-Barrie-peptide-MS2 #630-650 RT: 3.65-3.88 AV: 19 NL: 4.74E4
F: ITMS + p ESI Full ms2 326.82@cid25.00 [85.00-2000.00]
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MALDI-TOF MS of ARK+(Nε- methyl bis(propargyl))ST: 
 
 
 
 
 
 
 
 
 
 
 
 
[ARK(Nε- methyl bis(propargyl))ST]1+ 
ARK(Nε- mono(propargyl))ST 
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KDM4A, KDM4C, KDM4E Demethylation of ARK+ST experiment: we find no demethylation of 
the peptide by any enzyme up to 60 minutes 
 
KDM4A at 5 minutes (left), at 60 minutes (right) 
  
 
KDM4C at 5 minutes (left), at 60 minutes (right) 
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KDM4E at 5 minutes (left), at 60 minutes (right) 
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Table C.1.  Data collection and refinement statistics for KDM4A/Ni2+/JIB-04.a 
Resolution range (Å…) 35.31  - 3.207 (3.321  - 3.207) 
Space group P 2 21 21 
Unit cell 57.611 101.219 149.417 90 90 
90 
Unique reflections 14068 (1164) 
Completeness (%) 94.23 (79.73) 
Mean I/sigma(I) 8.24 (2.88) 
Wilson B-factor 70.80 
R-work 0.2182 (0.2676) 
R-free 0.2909 (0.3966) 
Number of non-hydrogen 
atoms 
5694 
Macromolecules 5674 
Ligands 20 
Water 0 
Protein residues 692 
RMS(bonds) 0.007 
RMS(angles) 1.26 
Ramachandran favored (%) 93 
Ramachandran outliers (%) 1.7 
Clashscore 18.35 
Average B-factor 72.80 
Macromolecules 72.70 
  ligands 80.90 
a Statistics for the highest-resolution shell are shown in parentheses. 
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1H-NMR of JIB-04 in (CD3)2SO: 
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13C-NMR of JIB-04 in CDCl3: 
 
 
KDM4A inhibition by JIB-04 was tested without pre-incubation of the holoenzyme and 
inhibitor using the discontinuous MALDI-TOF MS assay. First, the inhibition was tested using an 
HDM : FeII(NH4)2SO4·6H2O of 1:5, and only mild inhibition of KDM4A up to 500 µM JIB-04 was 
found. As the excess iron in solution could be interacting with JIB-04, the inhibition was next tested 
using 1:1 KDM4A:Fe(II), with the results shown in Figure C.1. Again, we find only mild inhibition 
of KDM4A up to 500 µM JIB-04.   
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Figure C.1. Mild inhibition of KDM4A by JIB-04 as found by MALDI-TOF MS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0μM JIB-04, no 
pre-incubation 
95% 
Demethylation 
500μM JIB-04, no 
pre-incubation 
80% 
Demethylation 
159 
 
BARBARA GORDON CASCELLA 
St. Louis, Missouri   ∙   (314) 308-7514   ∙   gordonbs@go.wustl.edu 
 
EDUCATION 
 
Ph.D., Chemistry, Washington University in St. Louis, St. Louis, MO         (2008-2014) 
A.M., Chemistry, Washington University in St Louis, St. Louis, MO         (2008-2012) 
B.S., Chemistry (ACS certified), Rhodes College, Memphis, TN         (2004-2008)  
 
 
RESEARCH EXPERIENCE 
 
Doctoral Research: Laboratory of Professor Liviu M. Mirica, Washington University in St. Louis 
 Kinetically characterized three JmjC-domain containing histone demethylases (JmjC-HDMs) 
with respect to primary and secondary substrates. 
 Discovered JmjC-HDMs have markedly low affinities for dioxygen through the 
development of a new in vitro oxygen consumption assay. 
 Designed, synthesized, and tested a library of compounds as potential specific inhibitors of 
JmjC-HDMs. 
Undergraduate Research: Laboratory of Dr. Loretta Jackson-Hayes, Rhodes College  
  
 Identified two novel genes, gmtA and gmtB, as encoding putative GDP-mannose transporters 
in the filamentous fungus Aspergillus nidulans.  
 Generated a stable gmtA-GFP expression construct used to determine the cellular 
localization of GmtA.  
 
 
SKILLS AND TECHNIQUES 
 
 Protein chemistry: protein expression; purification by affinity column, ion exchange, and size 
exclusion chromatography; western blotting 
 Enzymology: enzyme kinetics; assay development and optimization; inhibitor design and 
synthesis; molecular modeling 
 Characterization: UV-VIS, NMR, fluorometry, ESI-MS, and MALDI-TOF MS 
 Software: KaleidaGraph, Prism, Origin, OpenEye, PyMol, ChemDraw 
 
 
 
 
160 
 
HONORS AND AWARDS 
 
Teaching Citation Certification, Washington University in St. Louis         (2011-2014) 
Dean’s Dissertation Fellowship, Washington University in St. Louis      (2014) 
Departmental Teaching Award, Washington University in St. Louis       (2009) 
Senior Research Award, Rhodes College          (2008) 
Department of Defense Breast Cancer Research Program          (2010-2012)  
Undergraduate Research Fellowship, Merck Institute for Higher Education        (2007-2008) 
Vice President, Iota Sigma Pi, Rhodes College           (2006-2007) 
 
TEACHING EXPERIENCE 
 
 Teaching Citation Certification, issued to graduate students who seek to gain teaching expertise 
through seminars, workshops, and additional teaching experiences than those required by 
the graduate department (Teaching Center at Washington University in St. Louis).   
 Teaching assistant and POGIL recitation leader, Organic Chemistry I & II (Washington 
University in St. Louis). 
 Teaching assistant and POGIL recitation leader, General Chemistry (Chem 112, Washington 
University in St. Louis). 
 Guest lecturer, Inorganic Biochemistry (Chem 464, Washington University in St. Louis) 
 Teaching assistant and co-lecturer, Chemical Safety (Chem 599, Washington University in St. 
Louis).  
 Head teaching assistant and supervisor of eight graduate teaching assistants, Organic Chemistry 
Laboratory (Chem 262, Washington University in St. Louis). 
 Biology teacher of high school students, Honors- and Regular-level Biology (Westminster 
Christian Academy, Town and Country, MO). 
 Teaching assistant and recitation leader, General Chemistry (Chem 112, Washington University 
in St. Louis). 
 Teaching assistant and recipient of the Outstanding Teaching Award, Organic Chemistry 
Laboratory (Chem 252, Washington University in St. Louis) 
 Bench mentor of four undergraduate research assistants (Washington University in St. Louis) 
 
 
PUBLICATIONS 
  
Cascella, B.G. and Mirica, L.M. Survey of Simple Primary- and Secondary- Substrate Analog 
Inhibitors of Iron-Dependent Histone Demethylases. In preparation.  
 
Cascella, B. G. and Mirica, L. M. Kinetic Analysis of Iron-Dependent Histone Demethylases: α-
Ketoglutarate Substrate Inhibition and Potential Relevance to the Regulation of Histone 
Demethylation in Cancer Cells. Biochemistry 2012 51(44): 8699-8701 
 
161 
 
Jackson-Hayes, L., Hill, T.W., Loprete, D.M., Gordon, B.S., Groover, C.J., Johnson, L.R., Martin, 
S.A. GDP-mannose transporter paralogues play distinct roles in polarized growth of Aspergillus 
nidulans. Mycologia 2010 102(2): 305-310 
 
Jackson-Hayes, L., Hill, T.W., Loprete, D.M., Fay, L.M., Gordon, B.S., Nkashama, S.A., Patel, R.K., 
Sartain, C.V. Two GDP-mannose transporters contribute to hyphal form and cell wall integrity in 
Aspergillus nidulans. Microbiology 2008 154: 2037–2047 
 
PRESENTATIONS 
(* denotes presenter) 
Cascella, B.G.* and Mirica, L. M. Kinetic Analysis and α-Ketoglutarate Substrate Inhibition of Iron-
Dependent Histone Demethylases”, poster presentation. Washington University Graduate 
Research Symposium, 2014. St. Louis, MO.   
 
Cascella, B.G.* and Mirica, L.M. “Kinetic Analysis and α-Ketoglutarate Substrate Inhibition of Iron-
Dependent Histone Demethylases”, oral presentation. Washington University Biochemistry and 
Molecular Biophysics Retreat, 2013. Cedar Creek, MO.  
 
Cascella, B.G.* and Mirica, L.M. “Design of Specific Inhibitors for Histone Demethylases”, poster 
presentation. ACS Midwest Regional Meeting, 2011. St. Louis, MO. 
 
Gordon, B.S.* and Mirica, L.M. “Development of Specific Inhibitors of JmjC-Domain Histone 
Demethylases”, poster presentation. Washington University Biochemistry and Molecular 
Biophysics Retreat, 2010. Cedar Creek, MO.  
 
Gordon, B.S.*, Jackson-Hayes, L., Hill, T.W., Loprete, D.M. “Roles of two GDP-mannose 
transporters in cell wall stability in the filamentous fungus Aspergillus nidulans”, poster presentation. 
ASBMB Annual Meeting, 2008. San Diego, CA.  
 
VOLUNTEER AND LEADERSHIP ACTIVITIES 
 
 Volunteer at Grace and Peace Women’s Shelter, a refuge for homeless women in 
University City (Winter 2013, Winter 2014) 
 Volunteer at Catalysts for Change, an outreach program that seeks to inspire interest in 
STEM fields among young females from St. Louis city schools (2012, 2014) 
 
162 
 
 
